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 ABSTRACT 
1. Title: A Randomised, double blinded, controlled trial to compare the efficacy 
of extended spectrum antibioticwith narrow spectrum antibioticas prophylaxis 
in Cesarian delivery in preventing post Cesarian endometritis and surgical site 
infections. 
2. Department: Department of Obstetrics and Gynaecology, Christian Medical 
College, Vellore. 
3. Degree and Subject: M.S, Obstetrics and Gynaecology 
4. Word Count: 436 
Background: Cesariandelivery(CD) is the most commonly performed surgical 
procedure worldwide. Infection related complications of CD are common and is 
potentially life threatening. Administration of prophylactic antibiotic  prior to skin 
incision decreased the post CD infectious morbidity. Despite the prophylactic 
antibiotic there is a chance of 10-20% of postpartum infections due to different strains  
of micro-organisms and development of antibiotic resistant bacteria. To overcome this 
situation, adding  the extended spectrum antibiotic along with standard antibiotic 
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would further decrease the incidence of endometritis, wound infection, and therefore 
,length of hospital stay .There is need for more  randomized controlled trials to 
compare the efficacy of preoperative administration of extended spectrum antibiotic 
with standard narrow spectrum antibiotic in preventing  post CD  infectious morbidity. 
5. Objective: To compare the efficacy of a combination of antibiotics  with standard 
care( intravenous Cefazolin and intravenous Azithromycin vs intravenous Cefazolin  
and intravenous placebo) administered as prophylaxis for CD in the prevention of  
infectious morbidity following Cesarian delivery.  
6. Setting: Tertiary care Hospital  in South India. 
7. Methods: This was a randomised, double blinded, controlled trial, where mothers 
were   randomised to the study protocol once they the decision was made for CD. 
Each of the randomised woman received two injections prior to skin incision (Inj. 
cefazolin along with study drug or Inj. Cefazolin with a placebo) according to the 
randomisation code. After CD, these women were monitored in the ward for evidence 
of infection or any adverse event the drug might have caused. They were followed up 
till  42 days post delivery for any infectious morbidity (surgical site infections, urinary 
tract infection and readmission). 
8. Results:  The total number of women recruited into the study were 635. Of these, 37 
women had to be excluded due to following reasons. Three women who delivered 
vaginally after randomization, 3 women whose drug bottles was broken, and 1 women 
who was probably allergic to the study drug were excluded from the analysis. In 
addition, 25 women were lost to follow up and in 5, hospital numbers were not noted 
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and could not be entered into the study. The mean and SD for hospital stay for the 
mothers were 4.14 in the study group. Women who received extended spectrum 
antibiotic along with standard narrow spectrum antibiotic prior to skin incision had 
significantly less post CD endometritis, when compared with mothers who received 
standard narrow spectrum antibiotics alone (p >0.009) 
5. Conclusions: Extended spectrum antibiotic, when used as prophylaxis at CD resulted 
in significant reduction in  postoperative endometritis whereas reduction in surgical 
site infections, UTI and hospital stay  was not statistically significant when compared 
to narrow spectrum antibiotics. 
 
 
 
 
 
 
 
 
 
 
 
 
 14 
 
AIMS AND OBJECTIVES 
AIM: 
To compare the efficacy of extended spectrum antibiotic with standard narrow 
spectrum antibiotic  as  prophylaxis at CD in the prevention of postCD  endometritis 
and surgical site infection (SSI). 
OBJECTIVES: 
1.To compare the efficacy of extended spectrum antibiotics with narrow spectrum 
antibiotics on the following outcome ; endometritis, SSI, UTI, duration of hospital 
stay. 
2.To compare the safety profile of extended spectrum antibiotics. 
3.To compare the effect on other post operative complication like re admissions. 
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INTRODUCTION 
Cesarian Delivery (CD) is the most frequently performed surgery  in Obstetrics all 
over the world, to decrease the morbidity and mortality of both mother and neonate 
.The trend is seen to be  consistently increasing throughout the world (1).According to 
the WHO global survey 2004-08,  the overall CD rate increased overtime, from 26.4% 
to 31.2%  in the moderate and low human development index (HDI) countries(2) .CD 
has more risk of postpartum complications like puerperal infection, endomyometritis, 
surgical site infection(SSI) ,urinary tract infections,(UTI),pelvic abcess, 
thromboembolic events, increased blood loss, and anaesthetic complications. Women 
with previous LSCS have an additional risk of intra abdominal adhesions ,bowel and 
bladder injuries, presence of placenta accreta and cesarian hysterectomy. These further 
increase maternal and neonatal morbidity and mortality, and increase the length of 
hospital stay,cost and pose further economical burden to the family(3). Endometritis is 
one of the frequently  seen  complications arising in about 15-20%  of  CD and the 
incidence  is 5-85% (4). Most frequently, the microorganisms that are responsible for 
puerperal infections are polymicrobial, aerobic and anaerobic microorganisms. 
Ureaplasma urealyticum colonisation in the chorioamnion is most often seen in 
women with intact membrane and it is one of the independent predictors of 
subsequent endometritis (4).According to the CDC, SSI  is defined as ,an infection 
occurring within 30days after a surgical procedure(without any implant) .Based on 
post discharge surveillance,  the incidence  was found to be 9.9% (5).In 2014, 
Cochrane review recommended that prophylactic antibiotics should be administered to 
all CDs to prevent infectious morbidity . It was found that there was 60-70% reduction 
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in the incidence of SSI, endometritis and serious infectious complications when 
compared with no antibiotic prophylaxis (6). The prophylactic antibiotic   should have 
adequate tissue concentration, high safety, acceptable ecologically, easily 
administered and of low cost . According to the ACOG,SOGC, WHO, and NICE 
guidelines, the recommended prophylactic antibiotic is the first generation 
cephalosporin .The  ACOG,SOGC, WHO,NICE and CDC guidelines , with level A 
evidence recommend , that prophylaxis should be administered 60 minutes before the 
start of CD .The guidelines state that, there were no significant neonatal risks or 
antibiotic resistance to other microorganisms on account of prophylactic 
antibiotics(7). 
Despite the widespread use of prophylactic antibiotics, postpartum endometritis stays 
as  an common  complication following CD in about 10-20 % .The reasons behind this 
are ,that first generation cephalosporins do not cover Urea plasmaurealyticum , the 
most commonly seen microorganism causing  endometritis, and  narrow spectrum 
antibiotic alter the microorganism and increase  resistant organisms like anaerobes. 
This paves the way , to add  extended spectrum antibiotics like azithromycin, 
clindamycin, metronidazole or doxycycline (8).In many studies, azithromycin is 
proven to be effective due to its higher myometrial, adiposetissue, and placental 
concentration, low serum concentration,  adequate coverage forureaplasma 
urealyticum  and shown to be safely administered in pregnancy. In the present study 
we  aim  to  compare  the following outcome measures in the mother such as surgical 
site infection , endometritis , UTI ,length of hospital stay ,need for readmission, 
allergic reaction to study drug, and maternal death due to sepsis. 
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LITERATURE REVIEW 
Cesarian Delivery (CD) is the most commonly performed surgical procedure in 
obstetrics worldwide. The introduction of CD was for the  benefit of the mother and 
fetus , by decreasing  their morbidity and mortality and thereby improving their 
outcomes(1). According to the UNICEF , it is the most important global indicator for 
measuring access to obstetric services (9).The CD  rates are increasing rapidly and the 
current trend may result in even higher CD rates in the future(10)(11). There is a 50% 
rise in CD rates mostly due to an increase in the number of primary CD .Previous CD 
are an increasingly important determinant  factor of overall increase in the rates of CD  
in countries with a medium or low Human Development Index (HDI).(2). 
Trends of CD worldwide : 
 Ye et al, in 2015, analysed the rates of increase in CD from 2000-2012(12) 
Year World total least developed less developed more developed 
2000 12.0%(0.5-38.0) 2.0%(0.5-6.4) 13.1%(1.5-38.0) 19.5%(7.5-33.3) 
2012 15.5%(1.4-55.6) 5.2%(1.4-17.9) 16.9%(1.7-55.6) 26.9%(13.9-38.1) 
Relative 
Changes 
1.3% 
 
2.6% 
 
1.3% 
 
1.4% 
 
 In 2014, Kozhimannil et al ,conducted a retrospective multilevel analysis in the 
United States, to assess the incidence of CD and found that it  was 33% overall , the 
incidence for  primary CD being 22.0% (13).Vogel et al, in 2015,assessed the  trend of 
 18 
 
CD in 21 countries as a secondary analysis of  two WHO multicountry survey. The 
rates of CD were as follows(2) 
WHO  SURVEY(2) 
             Countries       Percentage for CD 
Very high HDI countries Argentina 35.1% 
Japan 19.8% 
High HDI countries Ecunda 40.3% 
Mexico 39.8% 
Peru 34.3% 
Sri Lanka 29.9% 
Brazil 27% 
Moderate HDI countries China 46.2% 
Paraguay 41.9% 
Thailand 34.1% 
Vietnam 35.9% 
Nicaragua 26.75% 
Philipines 17.9% 
India 17.7% 
Cambodia 14.7% 
Low HDI countries Kenya 16% 
Uganda 15% 
Nigeria 14.5% 
Democratic republic of the 
 congo 
Nigeria 5.3% 
Nepal 20.4% 
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The WHO  survey estimates the  annual expected rise in CD in developing countries 
to be  10-15%(14).In  47.2% of the  countries around the world, the CD rate increased 
by 15% . Latin America , the Caribbean along with Europe, North America and 
Oceania had the highest values(15,16).The overall CD rate increased overtime from 
26.4% to 31.2% according to a WHO global survey done in 2004-08. A population 
based study was done in Germany,  concluded that ,CD in those with secondary CDs 
show a rising trend ,from 17.2% in 1990 to 35.2% in the year 2012 (p<0.01)(17). 
Trends of CD in India : 
In the WHO‟s Global Survey  done by Vogel et al in 2015,the CD rate, which is an 
important criteria of the  HDI, was found  to be 17.7% in India(2).According to the 
National Family Health Survey2010, the incidence of CD in  India was facing  rising 
trends as well.(18). The  highest CD rate in India was found to be 17.9 % ,the highest  
were found urban population in Kerala, Goa, Andhra Pradesh and West Bengal 
are30% and  17.8% (19). 
Rates of CD in India(19) 
State Rural Urban 
Andra Pradesh 19.4% 32.25 
Assam 3.7% 17.4% 
Bihar 2.5% 7.6% 
Delhi 5.0% 12.6% 
Goa 23.7% 27.3% 
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Gujarat 5.5% 14.7% 
Haryana 3.1% 12.1% 
Himachal Pradesh 12.3% 15.4% 
Jammu and Kashmir 9.2% 29% 
Karnataka 11.6% 22.2% 
Madhya Pradesh 1.9% 13.6% 
Maharastra 7.7% 19.9% 
Orrisa 3.9% 12.8% 
Punjab 14.8% 19.6% 
Kerala 28.4% 33.5% 
Rajesthan 2.2% 9.9% 
Tamil nadu 19.8% 26% 
Uttar Pradesh 2.4% 12.7% 
West Bengal 5.8% 30.1% 
India  6.2% 17.8% 
 
In  the Christian Medical College and Hospital (CMCH), there were 14,276  deliveries 
in the year 2014.The total number of  CDs were 3985 and the CD rate was 29%. 
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The indications for CD were the following: non-reassuring fetal status (32%), labour 
arrest disorders (18%),multiple gestation (16%) suspected macrosomia (10%),pre-
eclampsia (10%),CD on maternal request (8%), maternal-fetal conditions (5%), other 
obstetric conditions(1%) and previous LSCS(20). 
Although there is an increasing trend in CDs, the reasons vary from social to medical , 
financial, cultural changes, and medicolegal considerations (21)(22).CD has become a 
safe procedure because of advances in Anaesthesia and, surgical skills and material, 
and therefore women opt for this electively. In addition, of  late ,there has been a rise 
in high risk pregnancies in the elderly, obese, infertility treated women(23). The 
prevalence of pre-gestational and gestational diabetes which were significant risk 
factors for a primary CD, have been increasing steadily (24). 
Some other factors that promote CD is prior CD, very low birth weight of  babies, 
multiple pregnancy, policy of elective CD for breech presentation and increasing 
maternal BMI(25).Extremes of neonatal birth weights were also associated with 
increased risk of CD(26). 
Complications of Cesarian delivery: 
Maternal : 
Immediate complications: 
1.Anaesthetic complication 10.5% ,the most common was haemodynamic 
fluctuations(27) 
2.Primary PPH (3-15%)(28) 
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3. Haematoma and reoperation seen more in LBW and gestational age less than 30  
weeks, blood loss >1000mL and need for blood transfusion (29) . 
4. Lowerurinary tract (LUT)injury remained relatively uncommon (0.3 %)(30) 
Remote complications: 
1. Postoperative pain 
2 .Postpartuminfection(endometritis,UTI,wound infection) (3) 
3. Thromboembolism(1 per 10,000 ) in the first week after CD(31) 
Complication after previous LSCS: 
1. Dense adhesion ,more significant after 4 CD(P>0.05)(32) 
2. Increased length of hospital stay 
3. Increased risk of bowel and bladder injury 
4. Placentaprevia and placenta accrete 
5. Increased need for blood transfusion 
6. Serious maternal morbidity is highly  increased when  the number of  CD 
increase.(33) 
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Fetal complications of CD: 
Planned CD is associated with increased neonatal respiratory complications(34).The 
prevalence of neonatal complications is more in  CD prior to the onset of  labour 
.These are mainly respiratory problems, which occur when do neat early term 
gestation(35).An Australian study in 2014,on neonatal outcome after elective CD 
showed that early term CD was associated with significant  increase in  fetal morbidity 
like admission to Neonatal critical care unit (NCCU) due to  severe respiratory 
morbidity needing  assisted ventilation mechanically or by continuous positive airway 
pressure(CPAP), transient tachypnoea of newborn(TTN) ,respiratory distress 
syndrome (RDS), primary pulmonary hypertension( PPHN) ,depressed at birth, low 
apgar score ,admission in NNCU 1-5 days, jaundice needing phototherapy, 
hypoglycaemia ,SGA and LGA(36) . 
Reasons for wanting to reduce the CD rate: 
CD on maternal request is a term adopted and endorsed by a 2006 National Institutes 
of Health (NIH) state-of-the-science conference that women have a right to request for 
elective CD, but the risks associated with this should be analysed. In 2013 , O‟Neill et 
al , in a systematic review of 11 articles ,found that there were associated risks .CD 
may increase the risk of stillbirth by 23%insubsequent pregnancy when compared 
with previous vaginal delivery (37).Repeat CD  has increased  rates of intra-operative 
complications, placental abnormalities such as placenta previa and accreta, and 
consequent gravid hysterectomy, iatrogenic prematurity of the baby ,  repeated CDs 
and difficulties during surgery, increased morbidity and mortality of the mother and 
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fetus, organ injury ,pain, anaesthetic complications, infections, cost, length of hospital 
stay, use of resources(38). 
Strategies to reduce CD rates: 
Robson ten group classification of LSCS: 
In order to propose and implement effective measures to reduce CD rates an 
appropriate classification of CD is required. In  2011, a systematic review  concluded 
that the Robson classification or 10-group classification would be  the best and  
internationally applicable classification for the same(39)(40). 
1. Nulliparous, singleton, cephalic, ≥37   weeks gestation, in spontaneous labour 
2. Nulliparous, singleton, cephalic,≥37 weeks gestation, induced or CD before 
labour 
     2a Nulliparous, singleton, cephalic,≥37 weeks gestation induced labour 
     2b Nulliparous ,singleton,cephalic, ≥37 weeks gestation  labour CD before 
labour. 
3. Multiparous (excluding previous CD,singleton,cephalic pregnancy, ≥37 weeks 
gestation in spontaneous labour  
4. Multiparous without a previous uterine scar,with singleton,cephalic pregnancy 
≥37 weeks gestation, ,induced or CD before labour 
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           4a. Multiparous without a previous uterine scar, with singleton, cephalic             
Pregnancy≥37    weeks gestation, ,induced  labour 
          4b. Multiparous without a previous uterine scar, with singleton, cephalic 
Pregnancy≥37   weeks gestation, CD before labour 
5. Previous CD, singleton, cephalic ≥37weeks gestation. 
6. All nulliparous with a single breech 
7. All multiparous with a single breech(including previous CD) 
8. All multiple pregnancies(including previous CD) 
9. All women with a single pregnancy in transverse or oblique lie (including those 
with previous CD) 
10. Allsingleton, cephalic,<37 weeks gestation pregnancies((including previous 
CD) 
Increase in CD rates are multifactorial in aetiology and can be safely  decreased by 
complex intervention. The evaluation and  identification of maternal risk factors, re-
evaluation and analysis of the indications  for induction of labour , counselling for 
trial of labor after CD (TOLAC) after detailed evaluation of  previous CD, and 
external cephalic version for non complicated breech presentation are most  important 
ways  to   lower the CD rates.(41)The meta analysis done by Nils chailet et al 
,revealed evidence based strategies for reducing the rates of CD .The safest  way to 
reduce  CD rates were upto the health care workers who should analyze and modify 
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their practice .Audit and feedback is an effective strategy, to improve the clinical 
practice, quality improvement and  can, thereby reduce CS by 13% when used alone 
and when used along with multifaceted strategy , can be reduced to 27%. Multifaceted 
strategies were effective  and strong in reducing CD rates.(42)Lotfi et al ,concluded 
that  the strategies that could  work  to reduce the CD are :  allowing qualified 
midwives to conducting normal vaginal deliveries,  skilled obstetricians in 
management of complicated deliveries, counselling the  community about the 
complications  of CD  and its outcome, educating patients regarding the chance of 
repeat CD ,by helping the  mothers to understand and  make a proper decision 
regarding their delivery and by promoting standards and developing regulations and 
legislations to provide good quality care.(43) 
Puerperal Infections: 
Puerperal sepsis is a leading cause of maternal mortality  in the world 
.(44)Endometritis (endomyometritis or endomyoparametritis), wound infection, 
mastitis, urinary tract infection, and septic thrombophlebitis are the major causes for  
puerperal infections and  most of them  occured after hospital 
discharge.(44)Septicemia, endotoxic shock, peritonitis or abscess formation are other 
serious maternal complications .There is a chance of increased infection in  post 
partum women  by  15-24% and  is a leading cause for preventable maternal 
mortalitily rate   .There is an  5- to 20fold  estimated increase in incidence of CD   in 
the future and CD  is the single most important risk factor for puerperal infection.(45) 
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Predisposing factors (46):  
1. Home birth in unhygienic conditions 
2. Low socioeconomic status 
 3. Poor nutrition 
4. Primiparity, anemia 
5. Prolonged rupture of membranes 
6. Prolonged labour 
7. Multiple vaginal examinations in labour 
8. Cesarian Delivery 
 9. Obstetrical maneuvers 
10. Retained products within the uterus  
11. Postpartum hemorrhage. 
12. Young maternal age  
14.  Presence of Ureaplasma in the genital tract 
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Causative micro-organism : 
The causative organisms are polymicrobial in nature. Aerobic and anaerobic 
infections were found in 48.1% patients who delivered  vaginally and in 58.4% 
delivered by  CD. The most common aerobic organisms were Staphylococcus 
epidermidis, E. coli, Enterocococci and Streptococci and , the most common  
anaerobic organisms  were the grampositive anaerobic cocci, Peptostreptococcus and 
Peptococcus, and Bacteroides species. When the prophylactic antibiotics were not 
given for CD,G vaginalis (39%)and anaerobes(45%)  were the most common 
microorganism associated with endometritis(47). Gestner et al  found  that anaerobic 
microorganism  played an important role in the pathology of post partum endometritis  
and that it was caused frequently by a polymicrobial aerobic  and  anaerobic  micro 
organism(25) Aerobic gram-negative infection  of  7%-25%   is seen in cultures done 
for postpartum infections.(48)Awadalla et al found that there was 16.8% of  aerobic 
and anaerobic micro organisms found in endometrial  cultures  from those who 
developed  endomyometritis. He stated that  there was a statistically significant 
relationship between positive cultures and the development of endomyometritis.(49) 
a.Endometritis: 
Endometritis is one of the most common complications which causes febrile 
morbidity after CD with an incidence of about 5%-85%.(50). Endometritis increased 
post CD hospital stay by 3 days and  hospital cost by $850 in a study done by 
donowitz et al(51) . It is five times more commonly seen following CD than vaginal 
delivery , which comprises15% to 20% of women delivered by CD (51). Postpartum 
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endometritisis caused when the vaginal organisms ascend to the endometrial cavity 
during labor and cause infection. (52) . Postpartum endometritis is the infection 
confined to the decidua - endometrium. This  infection can  extend  into the 
myometrium and is then called  endomyometritis and if it  involved  the parametrium 
then it is called as parametritis(53). At CD, highly virulent bacteria and Mycoplasma 
hominis predict the development of postpartum endometritis and during vaginal 
delivery, aerobic gram negative rods and bacterial vaginosis were the culprits.(54) . 
Despite the widespread use of prophylactic antibiotics, postpartum endometritis 
remains a common complication following CD. Chaim et al found that severe PIH , 
fetal distress, perinatal mortality, Apgar score less than 3 and 7 after 1 and 5 minutes 
were the  variable factors associated with postpartum endometritis.(55) Colonization 
of the chorioamnion with Ureaplasma urealyticum in women with intact membranes 
being delivered by Cesarian was a significant, independent predictor of subsequent 
endometritis(4). 
 Postpartum endometritis is defined as having a temperature of 100.4 F or more, 
associated with uterine tenderness , foul smelling or purulent lochia and leucocytosis 
more than 12,000 per mm3 without other pelvic infections. 
Prophylactic antibiotics at CD are highly effective in reducing postCesarian 
endometritis (56).According to the CDC/(NHSN)National Health care Safety Network 
surveillence, the definitions for specific type of infections( Endometritis(EMET) 
)must meet at least one of the following criteria:(57) 
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1. Patient  has organism cultured from endometrial fluid or tissue(including amniotic 
fluid) 
2. Patient has at least two of the following symptoms fever(>38.0C +/-),pain or 
tenderness( uterine or abdominal), or purulent drainage from uterus.   
Despite prophylactic antibiotics, endometritis occurs in 10–20% of women after CD, 
which further increases the morbidity. This could  be due to the development of 
antibiotic resistance in the microflora of the upper genital tract and abdominal wound  
(10) A combination of Clindamycin and Gentamicin  is appropriate to treat  
postpartum endometritis.(52) 
b)Wound infections/ SSIs : 
NHSN  data  showed an overall SSI  rate of 1.9% (2006-2008)(58).SSI were the most 
common health associated infections, accounting for 31% of all HAIs among 
hospitalized patients (59).Surgical site infection is one of the type of health care 
associated infection that occurs after an invasive procedure .According to NICE 
guidelines, SSI accounts for upto 20% of HAI s; 5% of patients who had surgery have  
SSI .(60)An  SSI may occur spontaneously  as wound discharge after 7-10 days from 
the time of surgery  or as life threatening complications. Most SSI s are caused by the  
micro organism from the patient‟s own body. Less SSI occur due to  exogenous 
microorganisms. Most of the SSI s are preventable by  measures taken during pre, 
intra and post operative care.(60)Surgical site infection is defined, according to the US 
Centers for Disease Control and Preventions (CDC), as an infection occurring within 
30 days after a surgical procedure   (without any implant) .SSI is a significant cause of 
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post-surgical morbidity and mortality which leads to  increase in the  length of the 
hospital stay , cost, and causing a  huge socioeconomic burden to the family . 
SSIs were classified as superficial or deep. A superficial wound infection was defined 
as infection of the skin and superficial tissues at the incision. Deep space infection 
was defined as infection involving the deep tissues such as the fascia and muscle 
layers(61).According to CDC guidelines CD without evidence of chorioamnionitis, 
would be classified as a clean contaminated surgical wound and if it was associated 
with chorioamnionitis, irrespective of the duration of rupture of membranes, it would 
be classified as dirty or infected surgical wound (62). A prospective cohort study done 
by Opoien et al found the incidence  of  SSI  to be  8.9%, when  a 30 day post-
operative follow up was done , when compared to 1.8% noted at the time of  hospital 
discharge(63).The incidence of SSI was higher following  elective CD according to 
postdischarge surveillance was 9.9%(5) .  
Risk factors for development of SSI  
1. Operating time > or = 38min  
2. BMI>30kg/m2 
3. Development of subcutaneous hematoma after the procedure for skin 
closure(64) 
4. Absence of antibiotic prophylaxis, duration of rupture of membrane(65) 
5. Internal fetal monitoring ,chorioamnionitis(66) 
6. African-American race(67) 
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7.  Number of vaginal examinations before surgery, duration of operation, vertical 
skin incision and category of surgeon (68) 
8. Anderson et al found that there was a strong relationship between obesity and 
surgical site infection (SSI) in women undergoing elective CD(69) and 
emergency CD. 
9. Twin delivery, hypertensives ,diabetes complicating pregnancy(pre gestational 
and gestational), (70). 
CDC Criteria for defining surgical site infection (SSI):(63) 
Superficial incisional SSI: 
Infection occur within 30 days after the operation and infection involves only skin or 
subcutaneous tissue of the incision and at least one of the following 
1. Purulent drainage, with or without laboratory confirmation, from the superficial 
incision. 
2. Organism isolated from an aseptically obtained culture of fluid or tissue from the 
superficial incision. 
3. At least one of the following signs or symptoms of infection : Pain or tenderness, 
localized swelling, redness, or heat and superficial incision  deliberately opened by 
surgeon, unless incision is culture – negative. 
4.Diagnosis of superficial incisional surgical site infection(SSI) by surgeon or 
attending physician 
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There are two specific types of superficial incisional SSIs:(71) 
1.Superficial Incisional primary(SIP)- a superficial incisional SSI that is identified in 
the primary incision in a patient that has had an operation with one or more incision 
(e.g., CD incision, chest incision for coronary artery bypass graft( CBGB) 
2. Superficial Incisional secondary (SIS)- a superficial incisional SSI that is identified 
in the secondary  incision in a patient that has had an operation with  more than one  
incision (e.g., donar site incision for CBGB) 
Deep incisional SSI 
Infection occurs within 30 days after the operation and infection involves deep soft 
tissue (eg. fascial and muscle layers) of the incision and at least one of the following 
1.Purulent drainage from the deep incisional but not from the organ/space component 
of the surgical site. 
2.A deep incisional spontaneously dehisces or is deliberately opened by a surgeon 
when the patient has at least one of the following signs or symptoms: 
fever(>38C),localized pain, or tenderness, unless site is culture-negative. 
3.An abscess or other evidence of infection involving the deep incision is found on 
direct examination, during reoperation,or by histopathologic or radiologic 
examination. 
4.Diagnosis of a deep incisional SSI by a surgeon or attending physician 
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There are two specific types of superficial incisional SSIs: 
1. Deep  Incisional primary(DIP)- a deep  incisional SSI that is identified in the 
primary incision in a patient that has had an operation with one or more incision (e.g., 
CD incision, chest incision for CBGB) 
2. Deep Incisional secondary (DIS)- a deep  incisional SSI that is identified in the 
secondary  incision in a patient that has had an operation with  more than one  incision 
(e.g., donar site incision for CBGB) 
Organ/Space SSI: 
Infection occurs within 30 days after the operation and infection involves any part of 
the anatomy (e.g. organ or spaces), other than the incision, which was opened or 
manipulated during an operation and at least one of the following: 
1. Purulent drainage from a drain that is placed through a stab wound into the 
organ/space. 
2. Organism isolated from an aseptically obtained culture of fluid or tissue in the 
organ/space. 
3. An abscess or other evidence of infection involving the organ/space that is found on 
direct examination, during reoperation, or by histopathologic or radiologic 
examination. 
4. Diagnosis of an organ/space SSI by a surgeon or attending physician. 
Do not report the following condition as SSI: 
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1. Stitch abscess (minimal inflammation and discharge confined to the points of suture 
penetration). 
2. Infection of an episiotomy or newborn circumcision site. 
3. Infected burn wound. 
4. Incisional SSI that extends into the fascial and muscle layers. 
 
Centers for Disease Control and Prevention’s National Healthcare Safety 
Network classification for surgical site infection (SSI). 
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MICROBIOLOGY 
Microorganism most commonly associated with wound infections are ureaplasma 
urealyticum, coagulase  negative staphylococci and enterococcus faecalis. Roberts et 
al found that wound  infections develop due to contamination from the lower genital 
tract during surgery and had a higher prevalence of enterococcus faecalis(72). Genital 
mycoplasmas are the most prevalent bacterium in post Cesarian wound infection.(73) 
Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus spp, and 
Escherichia coli are the most commonly identified microorganisms in surgical site 
infection. Methicillin-resistant staphylococcus aureus(MRSA),an antimicrobial-
resistant pathogen seen in increasing proportion of SSIs, is the most common 
pathogen seen in superficial incisional and complex SSI s(74) 
PATHOGENESIS: 
The important precursor of SSI is microbial contamination of the surgical site. 
The dose of bacterial contamination 3  microorganism virulence   =   Risk of surgical 
site infection   
__________________________________________________________________ 
Resistance of the host patient 
 
The risk of SSI is increased markedly when the surgical site is contaminated with 
>105   5microorganism per gram of tissue, then there is a chance of increased risk of 
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SSI(75). The role of cytokine is pivotal in both immunity and inflammation. Cytokine 
plays a complex role between host and exogenous microorganism(76). When the 
incision is made near the perineum or groin the chance of contamination with fecal 
flora is more. 
Risks  factors that can increase the development of surgical site infections(77): 
Patient Characteristics 
1.Age 
2.Nutritional status 
3.Diabetes 
4.Smoking 
5.Obesity 
6.Coexistent infections at a remote body site 
7.Colonization with microorganism 
8.Altered immune response 
9.Length of perioperative hospital stay 
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Operative Characteristics 
1. Duration of surgical scrub 
2. Skin antisepsis 
3. Preoperative shaving 
4. Preoperative skin preparation 
5. Duration of operation 
6. Antimicrobial prophylaxis 
7. Operating room ventilation 
8. Inadequate sterilisation of instruments 
9. Foreign material in the surgical site 
10. Surgical drain 
11. Surgical technique 
a. Poor haemostasis 
b. Failure to obliterate dead space 
c. Tissue trauma 
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Recommendation for  prevention of surgical site infection (78): 
1. Preoperative : 
a. Preparation 
1. Identify and treat all infection before elective surgery. 
2. Avoid preoperative hair removal. 
3. If hair removal needs to be done, use electric clippers 
4. Avoid preoperative hyperglycemia and adequate control of blood sugars. 
5. Instruct patient to avoid  or abstain peri operatively from smoking cigarettes,  
cigars, or other form of tobacco. 
6. Blood products to be given if indicated. 
7. Instruct patient to take a bath or shower before surgery. 
8. Complete wash and clean at and around the incision site. 
9. Use an appropriate antiseptic agent for skin preparation. 
10. Skin painting start as a concentric circle and move towards periphery 
11. Shorter perioperative hospital stay. 
12. Do not stop or taper the steroids preoperative, if the patient is on steroids. 
13. Nutritional support to prevent SSI. 
14. Preoperative mupirocin is not recommended for the prevention of SSI 
15. Wound space oxygen is not recommended to prevent SSI. 
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b. Surgical team members hand/forearm antisepsis: 
1. Short nail . 
2. Two to five minutes of hand and forearm upto elbow scrub with appropriate 
antiseptic solution 
3. Dry hands, sterile gown and gloves 
4. Remove hand or arm jewellery 
Infected and colonized surgical personnel management: 
1. The surgical personnel has to be educated and encouraged to inform their 
supervisory staff, when they have signs and symptoms of a transmissible infectious 
illness. 
2. To develop well defined policies concerning patient care responsibilities when the 
surgical personnel  have transmissible infections. 
3. When the surgical personnel has any signs and symptoms of transmissible 
infections obtain culture and exclude them from duty and adequately treat them. 
Antimicrobial prophylaxis: 
1.Antimicrobial prophylaxis to be administered according to guidelines and has to be 
administered within 1 hr before the skin incision to attain maximum tissue 
concentration (79) 
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2. Choose an antibiotic which is effective for the most common pathogen causing SSI 
for that particular procedure.  
3. Discontinue antibiotic within 24hrs after surgery. 
4.Dose of the antibiotics to be adjusted according to patient weight – 2gm Inj. 
cefazolin for patient weighing > 80kg and 3gms for > 120kg.(7) 
5. Prophylactic antibiotic should be re-administered for a prolonged surgery and 
increased blood loss.(7) 
Intraoperative: 
a.Ventilation: 
1a.For Positive pressure ventilation, guidelines of the American institute of architect – 
parameters for operating room ventilation(1996),need to be followed. 
Temperature – 68-73 F, depending on normal ambient temperatures 
Relative humidity - 30%-60% 
Air movement – from clean to less clean areas 
Air changes – Minimum 15 total air changes per hour and minimum 3 air changes of 
outdoor air per hour. 
b. Cleaning and disinfection of environmental surfaces 
1. Clean the affected area with EPA- approved hospital disinfectant before next 
surgery when there is visible soiling or contamination with blood or other body fluids. 
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Surgical attire and drapes: 
1. When entering the operating room wear a mask which fully covers the mouth and 
nose. 
2. Cap has to cover the entire hair on the head. 
3. Sterile gown and glove to be worn by all members of the surgical team. 
Asepsis and surgical technique: 
1. Asepsis to be maintained with intravascular devices like central venous catheters, 
spinal or epidural anaesthesia catheters and while administering intravenous drugs. 
2. Gentle tissue handling and complete haemostasis and obliteration of dead space. 
3. Drain has to be kept through a separate incision away from the operation site if 
required. 
Postoperative incision wound care: 
1. Sterile dressing has to be in place for 24-48hrs. 
2. Before and after dressing or any contact with operation site ,wash hands. 
3. Asepsis to be maintained while changing dressing. 
4. Patient and family members to be educated regarding wound care and the signs and 
symptoms of surgical site infections and to be reported if any occurs. 
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Methods for surveillance of SSI(80): 
1. The direct method 
2. The Indirect method 
3. Automated data system 
The direct method for surveillance of SSI: 
a. The most accurate method for SSI surveillance is the direct method , in which the   
postoperative  surgical site will be inspected daily from 24 to 48 hours  by the 
physician , physician extender , registered nurse , or infection prevention and control 
professional (81). 
b. The direct method is not practically easy and it is not used routinely due to its 
utilization of resource. 
c. The direct method is the gold standard for research. 
The Indirect method for surveillance for SSI: 
a. Retrospective analysis of patient medical records and microbiology report . 
b. Information from patient and surgeon 
c. Evaluation of readmission to ward and operating room 
d. Review of other information like coded diagnosis, coded procedures, operative 
reports, and antimicrobial prescriptions. 
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3. The indirect method for surveillance of SSI can be done by infection prevention 
control professionals and is less time consuming.. 
4.The indirect method for surveillance for SSI is specific and reliable and the 
sensitivity is 84%  to 89% and specificity is 99.8% when compared with the gold 
standard of direct surveillance of SSI.(82) 
5. The superficial incisional infections occurs post discharge, the indirect method for 
surveillance of SSI is not reliable and it cannot be used. (74) 
Automated data system: 
This can be used to expand the surveillance of SSI and by using hospital databases i.e; 
procedure and diagnosis code, use of antimicrobial and number of days administered, 
readmission to the hospital and operating room, surgical procedure data and 
demographic information into single database system.  Computer assisted ,laboratory 
– based and case confirmation by surgeons need less time and are more efficient than 
conventional method and permits with reliable accuracy for SSIs surveillance(83) 
Post discharge surveillance: 
Post discharge surveillance (PDS) for surgical site infections last  from 30 days for 
implant free procedures like CD and it can be maximum of upto 90 days for  implant 
surgeries(84).   Most SSI develop after hospital discharge(85) and it has been under 
estimated due to decline in the length of hospital stay ,more ambulatory service for 
surgical procedures and no post discharge surveillance. Mannien et al found a feasible 
and sensitive method of follow up to be post discharge follow up to the hospital and it 
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might be used internationally(86).PDS is important for estimation of incidence  of  
post-CD SSI . Meire Celeste et al says that 15-days of post discharge follow-up for 
post Cesarian SSI  is needed and it is appropriate to estimate the accurate rate of  post 
Cesarian  SSI and it  was shown to be sufficient(87).The proportion of SSIs found 
through the PDS can be different due to the method of PDS used, the operative 
procedure, the type of SSI and the settings.  Barwolff et al used  the Krankenhaus 
Infektions Surveillance System (KISS) for collecting data on surgical site infections 
(SSIs) following  CD and this  study showed that continuous surveillance and 
comparison with stratified reference data can be used to  reduce SSI infection rates 
after CD(88). Follow-up was not possible for all the patients, and so the incidence of 
post Cesarian SSI s was underestimated. With the use of PDS  the incidence of SSI s 
following elective CD was higher than the expected(5).The Scottish  national  data  
recommend a  procedure-specific approach to PDS, with direct observation of patients 
after  CD,  where  the length of hospital stay is short,  and  showed that for CD  the 
rate of SSI when PDS was performed was significantly higher than that when PDS 
was not performed  ,with significant p value P<.01  (89).A good method is important 
than the duration of post discharge surveillance for surgical site infections. 
Antibiotic Prophylaxis in Cesarian Delivery: 
CD has an increased risk of infectious morbidity when compared to vaginal delivery. 
The CD rate is on a steady upward trend, and as CD rates increase, so does the 
infectious morbidity. One needs to think about the most effective antibiotic to reduce 
this morbidity .In the 2014 Cochrane review, comparison was made using antibiotic 
versus placebo for the prevention of infection following CD .There were 95 studies 
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that were studied , in which 15,000 women participated. They were analysed in terms 
of maternal febrile morbidity, wound infection, endometritis , serious infectious 
complications, urinary tract infections, hospital stay , adverse effects  .The review 
recommended that prophylactic antibiotics should be administered to all women 
having CD to prevent infectious morbidity .It was found that there was 60-70% 
reduction in the incidence of wound infection, endometritis and serious infectious 
complications when compared with no antibiotic prophylaxis (78). Despite using 
prophylactic antibiotics, 10-20 % women develop  endometritis after CD which 
further increases the morbidity, hospital stay and economic burden to the family. The 
reason for this could be attributed to microfloral antibiotic resistance and changes in 
the microflora of the endometrium(29).It is important to use the most effective 
antibiotic with the least adverse effect .The choice of antibiotics should be based on 
factors such as  cost, half life safety, antimicrobial resistance and spectrum of activity. 
The principles for prevention of  surgical site (SSI)infection are skin asepsis, surgical 
technique and antibiotic prophylaxis(79). Prophylactic antibiotics decrease the amount 
of bacterial contamination at the time of surgery and at the surgical site and maintain 
adequate antibiotic level in the tissue at the time of surgery. 
Classification of antibiotics:   
A.Penicillins: 
Penicillins consist of a thiazolidine ring connected to a B-lactam ring to which is 
attached a side chain. The penicillin nucleus itself is the chief structural requirement 
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for biological activity. Penicillins are the oldest class of antibiotics and function by 
inhibiting cell wall 
synthesis (bactericidal) 
A1. Natural penicillins are based on the original penicillin-G structure. Examples 
include: 
penicillin G; procaine, penicillin V; benzathine 
A2. Penicillinase-resistant penicillins are active even in the presence of the bacterial 
enzyme that inactivates most natural penicillins. Examples include: cloxacillin; 
dicloxacillin; methicillin; nafcillin; oxacillin 
A3. Extended spectrum penicillins which are effective against a wider range of 
bacteria. 
Examples include: ticarcillin; piperacillin; carbenicillin; timentin 
A4. Aminopenicillins also have an extended spectrum of action compared with the 
natural penicillins. Examples include: ampicillin; amoxicillin 
A+. Penicillin combinations. Examples include: co-amoxyclav = ‟ampicillin+ 
clavulanic acid‟ (Trade names include: Augmentin; Clavamox; Tyclav); ‟ampicillin + 
sulbactam‟ (Trade names include: Ampictam; Unasyn) 
B. Cephalosporins:Cephalosporins have a similar basic structure to penicillins but 
with different side chains.They function by inhibiting cell wall synthesis 
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B1. First generation cephalosporins; examples include: cephalothin; cefazolin; 
cephapirin; cephradine; cephalexin; cefadroxil 
B2. Second generation cephalosporins; examples include: cefoxitin; cefaclor; 
cefuroxime; cefotetan; cefprozil; cefamandole, cefonicid; ceforanide, cefotiam 
B3. Third generation cephalosporins, examples include: cefotaxime; ceftizoxime; 
ceftriaxon; cefpodoxime; cefditoren; ceftibuten; ceftazidine; cefcapene; cefdaloxime; 
cefetamet; cefixime; cefmenoxime; cefodizime; cefoperazone; cefpimizole 
B4. Fourth generation cephalosporins, examples include: cefepime; cefpirome; 
cefclidine; cefluprenam; cefozopran; cefquinome 
B+: Cephalosporin combinations. Examples include: ‟cephradine + metronidazole‟; 
‟ceftriaxone+ metronidazole‟; ‟cloxacillin + gentamicin‟ 
C. Fluoroquinolones: The fluoroquinolones target the bacterial DNA gyrase and 
topoisomerase. They are potentbacteriocidal agents against a broad variety of micro-
organisms. 
Examples : ciprofloxacin; levofloxacin; lomefloxacin; norfloxacin; sparfloxacin; 
clinafloxacin; gatifloxacin; ofloxacin; trovafloxacin. 
 D. Tetracyclines :Tetracyclines are bacteriostatic antibiotics active against a wide 
range of aerobes and anaerobic gram-positive and gram-negative bacteria. They 
inhibit bacterial protein synthesis by binding to the 30S bacterial ribosome 
Examples include: tetracycline; doxycycline; minocycline. 
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Chloramphenicol is considered to have similar action to tetracycline 
E. Macrolides Macrolide antibiotics inhibit bacterial protein synthesis. Resistance can 
arise 
Examples include: erythromycin; clarithromycin; azithromycin 
F. Other beta-lactams (carbapenems) Carbapenems are beta-lactams that have a 
broader spectrum of activity than most other beta-lactam antibiotics 
Examples include: imipenem; meropenem; ertapenem; aztreonam, mezlocillin 
G. Aminoglycosides Aminoglycosides are first-line therapy for a limited number of 
very specific, often historically prominent infections, such as plague, turaremia and 
tuberculosis 
Examples include: streptomycin; gentamicin, kanamycin. 
H. LincosamidesLincosamides are protein synthesis inhibitors which bind to the 50s 
subunit of bacterial ribosomes and inhibit early elongation of peptide chain by 
inhibiting transpeptidase reaction 
Examples include: lincomycin; clindamycin. 
I. NitroimidazolesNitroimidazole is an imidazole derivative that contains a nitro 
group. It is used for the treatment of infection with anaerobic organisms 
Examples include: metronidazole, tinidazol 
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The most commonly used types of antibiotics are penicillins, cephalosporins, 
fluoroquinolones, tetracyclines  and macrolides. There are four groups of penicillin 
and four generations of cephalosporin, the newer cephalosporin generation has a 
extended spectrum of activity and they both have common chemical structure , 
bactericidal activity, acting through inhibiting cell wall synthesis. Fluroquinalones are 
the newer group of antibiotics, they are synthetic, and the newer class has broad 
sprectrum activity and act by interferinge with the ability of bacteria to make DNA.  
Tetracyclines  and Macrolides are derived from streptomyces bacteria and are broad-
spectrum bacteriostatic antibiotics and are also bacteriostatic in action, binding to 
bacterial ribosomes. Aminoglycosides are used to treat gram-negative bacteria . The 
major adverse effects of antibiotics need to be considered. It can be associated with GI 
symptoms like nausea, vomiting, diarrhoea, skin rashes and joint pain and rarely 
anaphylactic reaction .Wide use of antibiotics can cause the development of drug 
resistant strains of bacteria (80).Roberts et al found that there is a difference in 
ampicillin and cefazolin prophylaxis on endocervical and endometrial microorganism 
for postpartum infections, ampicillin for aerobic gram negative rods and cefazolin for 
enterococcus and anaerobes. But there was difference in endometritis cure rates even 
though they had similar therapeutic action (59).  
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Cochrane Review 2014 on  Comparison of different classes of  prophylactic antibiotics 
for the prevention of  post CD infectious morbidity (90) 
        Study  Antibiotic regimen             Outcome Result 
13 studies, 
4010 women 
 
 
Single cephalosporin 
 vs single penicillin 
Endometritis SSI UTI No significant 
difference  
between  two  
groups of  
antibiotics 
 
RR 1.11 
CI -0.81 to  
1.52 
 
RR0.83 
CI-0.38 
 to1.81 
 
RR1.48 
CI-0.89 
 to 2.48 
12 studies , 
2875 women 
Single  
cephalosporin  
vs penicillin  
combination 
 
RR 0.90 
CI – 0.60 to  
1.35 
RR 0.72 
CI-0.40 
 to1.30 
RR 0.66 
CI-0.17  
to 2.55 
No significant 
difference  
between two  
groups of  
antibiotics 
One study, 
147 women 
Cephalosporin 
combination  
vs single penicillin 
RR 2.70 
CI-0.65 
 to 11.55 
RR 2.02 
CI-0.42  
to 9.63 
    - No significant 
difference  
between two  
groups of  
antibiotics 
Two studies ,363 
women 
Cephalosporin 
combination vs  
 penicillin combination 
RR 0.33 
CI – 0.01 
 to 0.77 
RR1.23 
CI – 0.42 
 to 3.58 
- No significant 
difference  
between two 
 groups of 
 antibiotics 
Two studies, 
822 women 
First generation 
cephalosporin 
(cefazolin, 
cephazoline, 
Cephadrine + 
metronidazole) vs 
extended spectrum 
penicillin(pipercillin) 
RR 2.18 
CI – 1.30 
 to 3.66 
RR 2.02 
CI-0.92 
 to 9.62 
  - Higher incidence of 
endometritis 
 in first  
generation 
cephalosporins 
 but no  
difference in 
 SSI 
Eight studies, 
1882 women 
First generation 
cephalosporin vs 
aminopenicillin 
RR 1.09 
CI 0.69  
to 1.71 
RR 0.85 
CI 0.36 
 to 2.01 
RR 1.41 
CI 0.54  
to 3.70 
No significant 
difference  
between two  
groups of  
antibiotics 
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Six studies , 
2077 women 
 
Second generation 
cephalosporin  
vs extended  
spectrum penicillin 
 
RR 1.10 
CI-0.78 to 
1.54 
 
RR 2.37 
CI -0.64 
 to 8.73 
 
RR1.43 
CI-0.67  
to 3.07 
 
No significant 
difference  
between two  
groups of  
antibiotics 
Two studies 
 ,359 women 
Third generation 
cephalosporin 
(ceftizoxime, 
ceftriaxone) vs  
extended spectrum 
penicillin 
(piperacillin , 
 mezlocillin) 
RR 2.14 
CI- 1.14  
to 4.00 
-   - Endometritis is 
 more in 
cephalosporin 
 group 
Eight studies 
,1921  
women 
Second generation 
cephalosporin 
(cefotetan, 
cefamandole, 
cefonicid, 
cefoxitin, 
cefuroxime) vs 
aminopenicillin 
(ampicillin,  
ampicillin / 
sulbactum, amoxicillin/ 
clavulanic acid) 
RR 1.01 
CI-0.75  
to 1.35 
RR 1.14 
CI-0.47 
 to 2.78 
RR0.63 
CI- 0.11  
to 3.66 
No significant 
difference 
 between two  
groups of 
 antibiotics 
Seven studies, 
1904 women 
Third generation 
cephalosporin 
(ceftriaxone, 
ceftizoxime, 
cefotaxime, 
cefoperozone) vs 
aminopenicillin 
 (ampicillin/ 
cloxacillin, 
amoxicillin /clavulanic 
acid,ampicillin) 
RR-1.47 
CI- 0.89 
 to 2.42 
RR- 
0.49 
CI-0.27 
 to 0.90 
RR-0.52 
CI-0.10 
 to 2.80 
SSI – significant 
reduction in 
cephalosporin 
 group  
One study , 
72 women 
Fluroquinolones 
(Ciprofloxacin) vs 
penicillin (Ampicillin 
sulbactum) 
RR-1.17 RR-4.25 RR-0.09 Insufficient 
 data to provide 
 good evidence 
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One study , 
81 women 
Fluroquinolones( 
Ciprofloxacin) vs 
cephalosporin 
(cefotetan) 
RR-1.29 RR-2.15 RR-0.0 Insufficient  
data to provide  
good evidence 
One study, 
88 women 
Lincosamide 
(clindamycin) + 
aminoglycoside 
(Gentamycin) vs 
 penicillin 
( Benzyl penicillin) 
RR-1.46 RR-0.55 RR-0.0 Insufficient  
data to provide 
 good evidence 
 
Two studies, 
 118 women 
 
Beta-lactum 
(Azithromycin , 
imipenum) vs 
cephalosporin 
(cefazolin, 
cefotamine) 
 
RR-1.18 
 
RR-0.39 
 
RR0.0 
 
Insufficient  
data to provide 
 good evidence 
 
One study , 
 241 women 
 
Aminoglycoside 
 plus nitroimidazole 
(gentamycin 
+metronidazole) vs 
standard cocktail of 
antibiotic 
 
RR-0.81 
CI- 0.29 
 to 2.26 
 
RR-3.23 
CI- 0.34 
 to 30.64 
 
RR-1.08 
CI- 0.07 
 to 17.03 
 
No significant 
difference  
between two  
groups of 
 antibiotics 
 
 
Single-dose therapy has been proven to be effective when compared to multidrug 
group in most of the studies. It reduces the costs, potential toxicity, and the 
development of antibiotic resistant microorganism. Therefore, a single dose of an 
effective antibiotic, like a first generation cephalosporin, is the first-line drug of 
choice in CD as  prophylaxis. If the patient is allergic to penicillin or cephalosporin, a 
single dose of clindamycin with an aminoglycoside is an alternative drug of choice  
for prophylaxis in CD. 
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ACOG Guidelines for recommendation of antibiotic prophylaxis in CD (82): 
ACOG Level 1 Evidence: Recommendation for antibiotic prophylaxis in CD, a single 
dose of targeted antibiotic, such as a first-generation cephalosporin, is the first line 
drug of choice, unless there is significant drug allergy present. 
SOGC clinical practice guideline recommendation for antibiotic prophylaxis in 
CD : 
SOGC Level 1 Evidence: Recommendation : all  women undergoing elective or 
emergency CD should receive prophylactic antibiotic and the choice of antibiotic  is a 
single dose of a first generation cephalosporin .In addition, it is  recommended that if 
the procedure extended for more than 3 hours or if the estimated blood loss was 
>1500ml, an additional dose of the prophylactic antibiotic may be given  3 to 4 hrs 
after the initial dose and the dose of antibiotic could be doubled if the patient was 
morbidly obese. 
NICE guidelines(91): 
Prophylactic antibiotic should be offered to all women at CD to reduce the risk of 
postoperative infection. The choice of antibiotic should be an antibiotic which is 
effective against endometritis, wound infection and urinary tract infection, which 
occur in about 8%of women who have had a CD. 
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WHO recommendation for antibiotic prophylaxis at CD(92): 
Ampicillin and first generation cephalosporins show similar effectiveness in all the 
main outcomes such as endometritis , febrile morbidity, wound infection ,urinary tract 
infections ,hence it is not justified to use other antibiotics with extended spectrum or 
multiple drugs. 
The Swedish society of Gynaecology and Obstetrics guidelines for Antibiotic 
prophylaxis : 
The antibiotic should have adequate tissue concentration, high safety, acceptable 
ecologically, easily administered , low cost and recommended cephalosporin group as 
a first drug of choice. 
Time of Administration of prophylactic antibiotic in CD : 
The Cochrane systematic review in 2014 analysed 12 trials, based on high quality 
evidence ,the preoperative administration of prophylactic antibiotic for CD 
significantly decreases  the postpartum infectious morbidity like endometritis, wound 
infection, urinary tract  infection when compared to administration of antibiotic post 
cord clamp and there is no adverse outcome on the neonates(86).In Uganda , Dlamini 
LD et al found that administration of prophylactic antibiotic one hour  pre incision at 
CD, reduced the overall postoperative infectious morbidity, especially  endometritis 
,with a p value of 0.036(87). Baaqeel and Baaqeel et al found that preoperative 
prophylactic antibiotic significantly reduced the endometritis rate upto 41% and  
decreasing the other infectious morbidity like SSI and maternal febrile morbidity , 
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which is not statistically significant and there is no significant neonatal adverse 
outcome in this group(88).Kaimal et al showed , that there was a significant reduction 
in the number of post Cesarian  SSI which made the institution  change it‟s policy and 
administer  the pre incision prophylactic antibiotic in CD (89). CDC recommends 
antimicrobial prophylaxis to be administered according to guidelines and to be 
administered within 1 hr before the skin incision to attain maximum tissue 
concentration (66).Most of the guidelines ,with level A evidence recommend , that 
prophylaxis should be administered 60 minutes before the start of CD and there was 
no significant neonatal risks or antibiotic resistance to other microorganism(67,83–85)  
Chuanzhang et al  have done a multicentre randomized controlled trial and meta 
analysis  in a Chinese population regarding  the time of administration of antibiotic at 
CD and it was  found that there was no statistically significant difference in  
endometritis, Hence it was recommended that both , preincision or an after cord 
clamping administration of prophylactic antibiotic at CD and the long term follow up 
of the neonates is needed (93).  
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Prophylactic intravenous antibiotics administered before incision at Cesarian versus 
after neonatal   umbilical cord clamping (94): 
Outcome 
Effect size 
No.of studies 
 
No.of.                                        
Participants 
Statistical method        
Endomyometritis 
Cephalosporin 1 gm          10 5041 Risk Ratio 
(M-H,fixed,95%CI)  0.54(0.36,0.79)        
Cephalosporin 1 gm          5     2144 Risk Ratio 
(M-H,fixed,95%CI)0.58 
(0.30,1.12) 
Cephalosporin 2 gm         5 2807 Risk Ratio 
(M-H,fixed,95%CI)  0.51(0.33,0.83) 
Wound infection 
Cephalosporin 1 gm 10 5041 Risk Ratio 
(M-H,fixed,95%CI)               
0.59(0.44,0.81) 
Cephalosporin 1 gm            5 2144 Risk Ratio(M-
H,fixed,95%CI)0.55(0.30,1.01) 
    
Cephalosporin 1 gm 5 2897 Risk Ratio 
(M-H,fixed,95%CI)                 
0.61(0.43,0.88) 
UTI 
Cephalosporin 1gm 8 4001 Risk Ratio 
(M-H,fixed,95%CI)                    
1.02(0.65,1.59) 
Length of hospital stay 
Cephalosporin 1 gm 2 1342 Mean difference 
(IV,Fixed,95%CI)       
0.17(-0.30,-0.04)            
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Rationale for the use of extended spectrum antibiotic: 
Despite the widespread use of prophylactic antibiotics, postpartum endometritis 
remains a common complication following CD, about 10-20 %(38).These infections 
are polymicrobial in  nature ,which includes aerobes, anaerobes, ureaplasma or 
mycoplasma(37).There is a 3-8 fold increased risk of endometritis and wound 
infection if the amniotic fluid or chorion has ureaplasma urealyticum at the time of 
CD and the risk  of endometrtis is 6 fold, if associated with bacterial vaginosis 
(32,40,91).The first generation cephalosporins does not cover the ureaplasma 
urealyticum which is one of the most frequent microorganism responsible for 
endometritis, and the narrow spectrum antibiotic modifies the microorganism and 
increases the resistant organism like anaerobes (37,92).Therefore adding an extended 
cover antibiotic such as metronidazole, clindamycin or azithromycin is rational. 
Newton et al found that cefazolin and ampicillin  prophylax is altered the  endometrial 
and endocervical flora in patients with endometritis. Inspite of this, there is no 
difference in the cure rate. This warrants an addition of extended spectrum of 
antibiotic (29).In a cohort study done by Tita et al, it was found that the addition of 
azithromycin to standard narrow spectrum antibiotic as prophylaxis in CD 
significantly decreased the incidence of endometritis (93). It has been proven that the 
use of an extended spectrum antibiotic with coverage of  ureaplasma urealyticum like 
azithromycin and doxycycline as a prophylaxis in CD decreased the incidence of 
endometritis, wound infection and hospital stay  in a randomized clinical trial when 
compared with cephalosporins alone (41).In a retrospective observational study over 3 
consecutive periods Alan T.N Tita found that administration of extended spectrum 
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antibiotic with azithromycin significantly reduced the post CD infectious morbidity 
from 3.1% to 2.4% then 1.3%  with P value of < .002 and post CD endometritis  from 
19.9% to 15.4% then 6.3% with p value of <0.001(93,94).   
 
Tita et al, 2003  
Overview of published data on extended spectrum antibiotic prophylaxis: 
Study   Design  sample  
size  
Antibiotics  Endometritis  SSI  Hospital stay  
O’Leary  
1986  
RCT  123  Gentamycin  
(+Ampicillin)  
0.38(0.14,0.99)  0.98(0.06,15.0)  1.4 days shorter  
Pitt, 
2001  
RCT  224  Vaginal  
metronidazole  
(+Cefazolin)  
0.42(0.19,0.92)  1.67(0.41,6.81)  No difference  
Meyer, 
2003  
RCT  160  Metronidazole  
 (+Cefotetan)  
0.43(0.23,0.82)  N/A  1.4 days shorter  
Andrews, 
2003  
RCT  597  Azithromycin/ 
Doxycyline  
(+cefotetan)  
0.68(0.49,0.94)  0.22(0.05,0.99)  ½ days shorter  
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Why  should Azithromycin be used?: 
C38H72N2O12 
 
Azithromycin belongs to the azalide macrolides group of antibiotic which has  a 
similar action to erythromycin. It has a broad spectrum of activity which covers 
aerobic, gram positive anaerobic, intracellular microorganism. Azithromycin binds to 
the 50S subunit of the 70S bacterial ribosomes, therefore it inhibit RNA-dependent 
protein synthesis. Approximately 37% of the antibiotic is absorbed after an oral dose 
of 500mg, and the peak level occurs within 6 hrs of administration. Azithromycin has 
larger volume of distribution of about 23L/Kg and low serum level of 0.4microgram 
/ml , a prolonged half life and increased tissue levesl of about 68hr and  the 
intracellular concentration of the term pregnant women. Azithromycin metobolise 
through hepatic biliary excretion(95–97).Azithromycin levels are seen in high 
concentration in maternal uterine myometrium, adipose tissue and placenta and 
remains stable for upto 72hrs. The serum level of azithromycin in umbilical artery and 
vein were low and could be safely used to treat perinatal infections(98).Adverse 
effects of the drug includes nausea, vomiting ,abdominal pain and prolongation of QT 
interval in the older patient  . Sutton et al found that ,a single dose of 500mg 
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intravenous azithromycin before CD attained effective maternal plasma concentration 
more than MIC50 for most ureaplasma spp, and it had adequate plasma , myometrial 
concentration against ureaplasma urealyticum and it could be given >1hr before skin 
incision in CD as a prophylaxis for wound infection (99). 
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Rationale for this study 
Studies have shown that administration of extended spectrum antibiotic along with 
narrow spectrum as prophylaxis for CD has decreased the incidence of post infectious 
morbidity, but not many  studies have  specifically compared extended spectrum 
antibiotic use with standard narrow spectrum antibiotic with standard narrow spectrum 
antibiotic alone prior to skin incision. Therefore this randomised trial was designed to 
study the  efficacy of prophylactic antibiotic at CD in preventing post CD infectious 
morbidity  and the  maternal outcome. 
If this study can prove that administration of extended spectrum antibiotic along with 
standard narrow spectrum antibiotic pre incision  and post CD infectious morbidity are 
less without any adverse effect on mother and baby, the present practice of 
administering narrow spectrum prophylactic antibiotics at cesarian delivery can be 
changed.  
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METHODS 
Design 
This was a randomised, double blinded, controlled trial. 
Setting 
The study was carried out at the Christian Medical College, Vellore in  the 
Department of Obstetrics and Gynaecology . The study was conducted in the labour 
room, outpatient department and post natal wards of the department. This is a tertiary 
care hospital situated in Vellore, a town in south India. 
All mothers more than or equal to 37 completed weeks of gestational age were 
randomised to the study protocol once the decision was made for CD. 
Participants: 
 All women more than or equal to 37 completed weeks of gestation delivered by CD 
in Christian Medical College and Hospital Vellore were included in this study.  
Informed consent 
Informed consent was taken from patient or the relatives once  the decision  was made 
for CD (Patient information sheet and sample consent form – Annexure) 
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Key criteria 
Inclusion Criteria: 
All women of 37 completed weeks of gestation or more delivered by Cesarian 
delivery in Christian Medical College and Hospital Vellore were included in this 
study.  
Exclusion Criteria:  
1. Mothers with known allergy to Cephalosporin / Penicillin. 
2. Mothers who have received antibiotics within a week prior to the delivery or on 
antibiotic for GBS prophylaxis or chorioamnionitis.                                                          
3. Mothers with altered liver function (serum total bilirubin >3mg/dL).  
4. Mother with renal dysfunction (serum creatinine >1.5mg/dL).        
5. Mothers on medications such as carbamazepine or phenytoin. 
    6. Unable to take consent due to emergency CD(cord prolapsed, doubtful scar 
integrity)  
Intervention and comparator drugs 
Intervention: 
Women undergoing CD were randomised  according to the drug number to receive 
both injection cefazolin 1 gm iv and the study drug(Azithromycin or placebo) prior to 
skin incision. 
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Comparator: 
Injection cefazolin and placebo prior to skin incision 
Ethics clearance: 
The study was approved by the Institutional Research Board and Ethics 
committee.(Annexure 4) 
Methodology: 
This was a randomised, double blinded, controlled trial, where mothers were 
randomised to the study protocol once they the decision was made for CD. Each of the 
randomised woman received two injections prior to skin incision (Inj. cefazolin along 
with study drug or Inj. Cefazolin with a placebo) according to the randomisation code. 
After CD, these women were monitored in the ward for evidence of infection or any 
adverse event the drug might have caused. They were followed up till 42 days post 
delivery for any infectious morbidity (surgical site infections, urinary tract infection 
and readmission). 
Patient information sheet  and consent forms for the clinical trial were kept along with 
the consent form for the CD in the labor room..  Consent  for  the  elective  CD was 
taken  during   the antenatal  visits in the outpatient department  and consent  for  the 
emergency CD and the unbooked women was taken  at  admission  into  the  labour 
room.  
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The sample size was calculated to be a total of 1996 women participants. They were 
randomised to 2 groups, group 1,consisting of 998  mothers  to  receive IV  cefazolin 
1 gm (>80kg-2gm) and IV  Azithromycin 500 mg in 250 mL NS  over 1 hour pre 
incision.  Group 2 ,to have 998  mothers who will  receive  IV Cefazolin 1gm  and IV 
placebo in 250mL NS  over 1 hour pre incision, according to  computer generated 
randomisation drug number. 
After the CD, the mother was to be followed up in the postnatal ward upto discharge, 
and  untill 6 weeks postpartum for the following outcome measures. 
The primary outcome measures in the mother were the following: infectious 
morbidities- post operative surgical site infection, endometritis, UTI  and length of the 
hospital stay. 
Endometritis was diagnosed according to CDC guidelines: maternal fever  >100.4
0
F 
on 2 separate occasions with uterine fundal tenderness, or foul smelling vaginal 
discharge. Urinary tract infection was diagnosed according to urine culture. and 
sensitivity reports. SSI was diagnosed according to CDC guidelines and the length of 
hospital stay was calculated from the time of delivery until discharge form the 
hospital. 
Mother were advised to follow up at the end of 42 days for the routine postnatal 
review or earlier if they had any fever, symptoms of urinary tract infections, pus or 
serous  discharge from the operated site, redness ,swelling or wound gaping. Those 
who were unable to attend the postnatal review at the end of 42 days were called by 
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the principle investigator and enquiries made about their well being and about any of 
the above symptoms and the treatment for the same. 
 Target sample size and rationale  
The sample size to compare the effect of extended spectrum antibiotic along with 
standard antibiotic on the rate of infection in the mother was found to be 996 in each 
arm with 90% power, at 5% level of significance, an anticipated difference of 9% 
(based on a study done by Tita et al) as mentioned earlier with a 20% loss to follow 
up. 
 Formula: 
 
Where P=0.235Q=0.765 
is the alpha level of significance  is level for 90% power d = p1-p2P = 
average of p1 and p2 
 Method of randomization 
Computer generated block randomization sequence 
Method of allocation concealment 
Serially numbered opaque envelopes with the treatment allocation were provided to 
the Principle Investigator which were opened at the time of treatment administration . 
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Blinding and masking:  
The participant , the care givers and the Principle investigator (who is the outcome   
assessor) were blinded to the treatment allocation . 
Data Analysis 
Data entry was done into Microsoft Excel spreadsheets and Epidata software.  
Analysis was done using SPSS 16 software. Mean and standard deviation were 
calculated for normally distributed data. Appropriate tests for significance –Chi square 
test, Levene's Test for Equality of Variances, t-test for Equality of Means were 
performed.   
Adverse effects with IV Cefazolin and IV Azithromycin were thought to be unlikely. 
However, monitoring was done after administration of the drug.  All data was 
submitted to the institutional Data Safety Monitoring Board for review at the interim 
period and at the end of the trial. 
Validation of Drugs used in the Trial 
The drug Cefazolin and Azithromycin are commonly given during pregnancy and 
hence it was considered to be safe to administer to the mother, and not sent for 
validation. The results were not known to the investigators treating team, the 
caregivers / nursing staff or the patient‟s family. 
Data Safety Monitoring Board 
The results were presented to the DSMB for their approval. 
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Figure1 :Schematic representation of the  trial 
 
Women more than 37 
completed weeks of gestation 
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included in the study
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explaining about the 
study in detail
Prospectively included in 
the study
Group1 received  injection.Cefazolin IV and the 
study drug and  group 2 received Inj.Cefazolin and 
IV placebo in 250ml NS  before the skin incision for 
over 1 hour  in the labor room according to the 
computer generated randomisation number
Women  who were not 
allergic to the drug ,will  
continue the drug
Randomised into the trial
Informed consent not 
given by patient or those 
who did not meet the 
inclusion criteria
Excluded from the  study
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Figure 1: Shows that mothers were randomised to the study protocol once they the 
decision was made for CD were told about the study  in detail and informed consent 
was taken from the patients who met the inclusion criteria. After obtaining the 
informed consent, patient were included in the study and the rest were excluded from 
the study. 
Women ,who were included in the study  would be given injection cefazolin IV and 
the study drug  in 250 ml NS  for 1 hr in the labor room(either the placebo or the drug 
) according to the computer generated randomisation number, prior to skin incision .In 
women who had allergy to the drugs ,it was discontinued and patient was excluded 
from the study(As represented in figure 1 above).  
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Figure 2: Schematic representation of follow up of the patients 
Figure 2 : Shows the follow up of the study patients. They were monitored  in the 
postnatal wards during their hospital stay and  evidence of endometritis, surgical site 
infection , urinary tract infection, length of hospital stay were recorded. 
Patients once discharged from the hospital were advised  review at the end of  6 weeks  
postpartum or earlier if there is any signs and symptoms of Endometritis, urinary tract 
infection and SSI. 
Patients who could not report at the end of 6 weeks postpartum were called by 
principal investigator and enquired about any signs and symptoms of urinary tract 
infection and SSI and the treatment taken for the same. 
Patients were monitored in the postnatal ward for  primary outcome (clinical 
evidence of endometritis, UTI , SSI and the length of the hospital stay ).
patients were advised to come for postnatal review at the end of 45 days from 
delivery or earlier if any signs and symptoms of infecions either UTI or SSI
Patients who could not come for postnatal review were called by principal 
investigator and enquired about any evidence of the above infectious morbidity 
and the treatment for the same.
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RESULTS 
A total of 635 patients were recruited into the study over a period of 5 months(March 
2015 to July 2015).The consort diagram is given below. Out of the total 635 patients 
that were enrolled, the serial number of the enrolment drug was inadvertently missed 
in 6 of them. Three  patients who were expected to have CD, delivered normally after 
randomization, and in another 3 ,the drug bottles were accidently broken. Twenty five 
of the women were lost to follow up due to various reasons. Among 598 mothers 
included in the analysis ,302mothers in Group 1, received extended spectrum 
antibiotic along with standard narrow spectrum antibiotic(Inj. Azithromycin with 
Inj.cefazolin)and  296 mothers in Group 2, received standard narrow spectrum 
antibiotic with placebo(Inj.cefazolin with placebo). 
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Demographic Characteristics of the study population Distribution of the age of 
the women: 
Table 1 :Distribution of the age of the women 
 Group 1 Group 2 Total P value 
No.of patients 302 296 598 
0.373 
Mean age 27.59 27.28 27.43 
SD 4.38 4.65 4.51 
Minimum age 17 17 17 
Maximum age 39 40 40 
 
In this study, there were 302 patients in group 1, and 296 in group 2.The mean age in 
group 1 was 27.59 years and the standard deviation was 4.38.The mean age in group 2 
was 27.28 years and the standard deviation was  4.65 (P value - 0.373).There was no 
significant difference between the maternal ages in both groups. 
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Distribution of the Gestational age at CD: 
Table 2 : Distribution of gestational age : 
 Group 1 Group 2 Total P value 
No.of patients 302 296 598 
 
 
 
   0.721 
Mean 38.71 38.74 38.7 
SD 1.13 1.06 1.09 
Minimum  
gestational age 
37 weeks 37 weeks 37 weeks 
Maximum  
gestational age 
41 weeks 42 weeks 42 weeks 
 
Overall, the mean gestational age was 38.7 weeks and the standard deviation was 
1.09. The maximum gestational age was 42 weeks and minimal gestational age was 37 
weeks. In group 1, there were 302 patients; the mean gestational age was 38.71 weeks  
with a  standard deviation of 1.13. The maximum gestational age was 41 weeks and 
minimum gestational age was 37 weeks. In group 2, there were 296 patients, the mean 
gestational age was 38.74 weeks, with standard deviation of 1.06. The maximum 
gestational age was 42 weeks and minimum gestational age was 37 weeks (P value  
0.721).There was no difference in the gestational ages between the groups. 
 
 
 76 
 
Distribution of  gravidity: 
Table  3  : Distribution of women according to gravidity  
Gravidity Group 1 Group 2 Total P value 
Primigravidae 107 (35.4%) 128 (43.2%) 235(39.3%)  
      0.054 
Multigravidae 195 (64.6%) 168 (56.8%) 362(60.7%) 
Total 302  296 598 
Figure 1: Distribution of women according to gravidity 
 
There were 235(39.3%) primigravid and 363 (60.7%) multigravid women in the study. 
Ingroup 1,there were 107(35.4%) primigravidae and 195 (64.6%) multigravidae, when 
compared to 128(43.2%) primigravidae and 168(56.8%) multigravidae in group 2. 
There were significantly more  number of multigravidae, when compared to 
primigravidae ( P value- 0.054). 
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Distribution of  BMI 
Table 4:Distribution of BMI  
BMI Group 1 Group 2 Total P Value 
<18.5kg/m2 6(2.0%) 4(1.4%) 10(1.7%)  
 
 
 
0.549 
18.5-24.9kg/m2 93(31.4%) 82(28.4%) 175(29.9%) 
25-29.9kg/m2 143(48.3%) 138(47.8%) 281(48.0%) 
>30kg/m2 54(18.2%) 65(22.5%) 119(20.3%) 
 
Figure 2 :Distribution of  BMI 
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The body mass index (BMI) was calculated from the recorded weight at first antenatal 
visit, as most of them did not know their pre pregnancy weight. There were 10 (1.7%) 
women in group 1, and 6(2.0%) in group 2 who fell into the underweight category. In 
the normal weight category, there were 93(31.4%) women in group 1 and 82(28.45%) 
in group2. The overweight category had 143(48.3%) in group1 and 138(47.8%) in 
group 2, whereas in the obese category there were 54(18.2%) women  in group1 and 
65(22.55%)in  group2. 
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Obstetric  Risk factors-Univariate Analysis 
Prevalence of Antenatal risk factors in study population 
Table 5 : Prevalence of Antenatal risk factors: 
Antenatal risk factor Group 1  Group 2        Total P value 
HDP 32(29.6%) 25(24.0%) 57(26.9%)  
 
0.176 
Diabetes 56(51.9%) 52(50.0%) 108(50.9%) 
Hypothyroid 6(5.6%) 15(14.4%) 21(9.9%) 
Others 14(13.0%) 12(11.5%) 26(12.3%) 
No risk factors 194(32.4%) 192(32.1%) 386(64%) 
 
Figure 2:Prevalence of  Antenatalrisk factors 
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There were 57(26.9%) women with hypertensive disease of pregnancy (HDP).This 
included  pre- eclampsia,  eclampsia, chronic hypertension, gestational hypertension 
and superimposed pre-eclampsia. In  group 1,there were  32(29.6%) women and in 
group 2, 25(24%).There were 108 (50.9%) women with diabetes and  this included pre 
gestational and gestational diabetes managed with medical nutritional therapy, oral 
hypoglycaemic agents and / or insulin. Group 1 had 56(51.9%)  with diabetes and 
group 2had 52(50.0%). There were a total of 21 (9.9%) women with hypothyroidism 
complicating pregnancy ,6(5.6%) in  group 1 and 15(14.4%) in group 2.A few 
diseases like bronchial asthma, tuberculosis treated, Hepatitis B Positive diseases were 
included under "others" and constituted 26 (12.3%) of the total, 14(13%) in  group 1 
and 12(11.5%) in group 2.There were 386(64.5%) women without any associated 
antenatal risk factors , 194(64.2%) in group 1 and 192(64.4%)  in group 2.There were 
more HDP and diabetes  disease complicating pregnancy in group 1 compared with 
group 2  ,but it was not statistically significant 
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Distribution of Hemoglobin (Hb) levels: 
Table6 : Distribution of Hemoglobin levels: 
Hb Group 1 Group 2 Total P value 
>11gm% 244(81.3%) 247(84.0%) 491(82.7%)  
    0.453 
7-10.9gm% 55(18.3%) 47(16.0%) 102(17.2%) 
<7gm% 1(0.3%)    - 1(0.2%) 
Figure 3: Distribution of Hemoglobin levels: 
 
There were 491(82.7%) women with normal haemoglobin (> 11gm/dl) in all. This 
assessment was carried out at first antenatal visit, irrespective of the gestational age 
.In group 1, there were 244(81.3%) with normal Hb and in group 2 ,247(84%) . Mild 
and moderate anemia  (Hb level between 7and10.9gm/dl ) was present in, 55(18.3%) 
of group 1 women and 47(16%) of group 2.There was one patient with severe anaemia 
in group 1 ,none in group 2 .  
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Duration ofprelabour Rupture of membranes (PROM) 
Figure  4: Duration of PROM: 
 
Table7 : Duration of PROM 
Duration of  
rupture of membrane 
Group 1 Group 2 Total P value 
<6hrs 29(21.6%) 28(20.3%) 57(21.0%) 
 
     0.944 
6-12hrs 58(43.3%) 61(44.2%) 119(43.8%) 
13-18hrs 47(34.6%) 49(35.1%) 96(34.8%) 
The duration of PROM was analysed in the study population. There were 29 (21.6%) 
patients in group 1 and 28(20.3%) patients in group 2 who had less than 6 hours of  
PROM .There were 58(43.3%)in group 1 ,61(44.2%) in group 2 who presented with 
6-12 hours of PROM .Women who had 13 -18hours of PROM made up the 
remaining, 47(34.6%)in group 1 ,49(35.1)in group 2 . There was no significant 
difference between the 2groups. 
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Distribution of Elective and EmergencyCD : 
Table 8 : Elective and Emergency CD 
Type Group 1 Group 2 Total P Value 
Emergency CD 168(55.6%) 183(61.8%) 351(58.6%)  
0.135 
 Elective CD 132(44.0%) 112(38.0%) 244(41.0%) 
Figure5 :Elective and Emergency CD 
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There were a total of 7,200 deliveries during the study period. The total number of CD 
during the same period was 2,100. There were 168(55.6%) patients in group 1 and 
183(61.8%)in group 2 who underwent emergency CD. Of group 1,132(44%),and of 
group 2,112(38%) women had elective CD. The rate of emergency CD was 
more(55.6% and 61.8%)in groups 1 and 2,respectively,when compared with elective 
CD and the P value was 0.135.  
Distribution of indications for CD 
Table 9:Indications for emergency CD 
Indication      Group 1      Group 2       Total P value 
NRFS 60(44.4%) 86(60.1%) 146(52.5%) 
0.009 
Abnormal Lie in labour 9(6.7%) 4(2.8%) 13(4.7%) 
Labour dystocia 27(20%) 12(8.4%) 39(14%) 
Failed induction 36(26.7%) 35(24.5%) 71(25.5%) 
Previous LSCS Declined 
 TOLAC 
25(75.8%) 20(50%) 45(61.6%) 
Breech with  
PROM 
6(18.2%) 13(32.5%) 19(26%) 
IVF pregnancy 2(6.1%) 7(17.5%) 9(12.3%) 
Others 3(2.2%) 6(4.2%) 9(3.2%) 
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Table 10: Indication for elective CD 
Indication  Group 1  Group 2  Total  P value  
Declined TOLAC  80(61.5%)  70(63%)  150(62.2%)  
0.995  
Breech presentation  20(15.4%)  18(16.2%)  38(15.8%)  
Non vertex 1
st
 twin  4(3.1%)  2(1.8%)  6(2.5%)  
>1 Previous  LSCS  13(10.0%)  11(9.9%)  24(10.0%)  
Inter delivery interval 
<18months  
7(5.4%)  6(5.4%)  13(5.4%)  
Previous preterm LSCS  4(3.1%)  3(2.7%)  7(2.9%)  
IUGR with abnormal 
 Dopplers  
2(1.5%)  1(0.9%)  3(1.2%)  
 
When considering the  indications for CD, the commonest was for non reassuring fetal 
heart (NRFS), 60(44.4%) in group 1 and 86(60.1% )in group 2 .Among the elective 
CD, the  commonest indication was for those women with previous LSCS who 
declined Trial of Labour after Cesarian delivery(TOLAC) and they 
constituted80(61.5%)in group 1 and 70(63.1%)in group 2. On the whole, there were 
more number of emergency CD when compared to elective CD and this was 
statistically significant with a P value of 0.009. 
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Time duration for CD, intra operative blood loss, need for Peri operative blood 
transfusion-univariate analysis 
Table 11 : Time duration for CD, intra operative blood loss and need for peri operative 
blood transfusion: 
Time duration of surgery 
Duration Group 1 Group 2 Total P value 
<1 hr 
1-2 hr 
>2 hr 
288(96%) 
11(3.7%) 
1(0.3%) 
286(97.3%) 
7(2.4%) 
1(0.3%) 
574(96.6%) 
 18(3.0%) 
2(0.3%) 
 
0.659 
Intra operative blood Loss 
<500mL 
600 – 1000mL 
1100 – 2000mL 
252(84.0%) 
44(14.7%) 
4(1.3%) 
234(79.1%) 
60(20.3%) 
2(0.7%) 
486(81.5%) 
104(17.4%) 
6(1.0%) 
0.152 
Peri operative blood transfusion 
Yes 
No 
6(2.0%) 
295(98.3%) 
8(2.7%) 
285(94.2%) 
14(2.4%) 
573(96.3%)                  
0.599 
Univariate analysis was done for duration of surgery , intra operative blood loss, and 
the need for peri operative blood transfusion . Most of the CD were completed within 
one hour,288(96%)in group 1 and 286(97.3%) in group 2.Most of the women in both 
groups had  blood loss  less than 500ml, 252(84%) in group 1 and 234(79.1%) in 
group 2.There were 44(14.7%)women in group 1 and  60(20.3%)  in group 2 who had 
blood loss between 600-1000ml and  a small number who lost 1100-2000 ml , 
4(1.3%) in group 1 and 2(0.7%)in group 2. Only  6(2%)in group 1 and 8(2.7%) 
women required  blood transfusion. 
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Incidence of Intra-operative complications: 
Table 12: Intraoperative complications : 
Intraoperative complication Group 1 Group 2 Total P value 
PPH 
Bladder injury 
Extension of uterine incision 
7(53.8%) 
1(7.7%) 
5(38.5%) 
7(58.3%) 
       - 
59(41.7%) 
14(56%) 
1(4.0%) 
10(40%) 
 
0.618 
Figure 7:Intraoperative complication
 
 
When  considering postpartum hemorrhage (PPH),group 1 had 7(53.8%) and 
7(58.3%) in group 2 .In the present study,other intre-operative complications were 
related to extension of the uterine incision,which numbered 5(38.5%)in group 1 and 
5(41.7%) in group 2.One patient had bladder injury in group 1. 
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Analysis of the Primary Outcomes 
Figure8  :Evidence of endometritis,SSI and UTI
 
Evidence of endometritis 
Table 13:Evidence of endometritis 
Evidence of endometritis Group 1 Group 2 Total P value 
Yes 5(1.7%) 17(5.8%) 22(3.7%) 0.009 
No 295(98.3%) 282(94.2%) 573(96.3%) 
 
On analysing the data ,it was found that there were a total of 22(3.7%) women with 
evidence of endometritis, 5(1.7%) in group 1 and 17(5.8%) in group 2. There was 
statistically significantreduction (p value of 0.009) of evidence of endometritis with 
the use of extended spectrum antibiotics as prophylaxis at CD. 
1.7% 3.7%
38.5%
5.8% 5.5% 5%
0
5
10
15
20
25
30
35
40
45
Endometritis Wound infection UTI
Outcomes
Group 1
Group 2
 89 
 
Incidence of Surgical site infections(SSI) 
Table 14: Surgical site infections 
SSI  Group 1 Group 2 Total P value 
Yes 11(3.7%) 16(5.5%) 27(4.6%) 0.329 
No 287(96.3%) 276(94.5%) 563(95.4%) 
The  overall incidence of SSI  in the study population was 27(4.6%) , of which, group 
1 had11(3.7%) and group 2 had 16(5.5%). Eventhough it was not statistically 
significant the rate ,of SSI showed a trend towards lesser incidence of SSI with 
extended spectrum antibiotics. 
Urinary tract infection (UTI): 
Table 15:Incidence of urinary tract infection 
Incidence of 
Urinary tract infection 
Group 1 Group 2 Total P value 
Yes 5(71.4%) 2(28.6%) 7(100%)     0.265 
No 297(50.3%) 294(49.7%) 591(100%) 
 
The overall incidence of UTI in the study population was 7(13.2%) . In group 1 there  
were 5(38.5%) and2(5%) in group 2. The incidence of UTI in group 2  appeared to be 
less when compared to group 1, even though it was not statistically significant. 
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Table 16: Length of the hospital stay 
Length of hospital stay Group 1 Group 2 P value 
3-5 days 272(90.1%) 255(86.1%)  
0.139 
6-10 days 28(9.3%) 35(11.8%) 
>10 days 2(0.7%) 6(2.0%) 
 
Figure9 : Length of hospital stay 
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 91 
 
 
In the present study, the duration of  hospital stay was analysed , as 3 categories. 
There were 272(90.1%) in group 1 and 255(86%)in group 2, whose hospital stay 
lasted from 3-5 days, which was considered as normal following CD. There were 
28(9.3%)in group 1 and 35(11.8%)in group 2 who had a hospital stay from 6-10 days. 
There were 2(0.7%) women in group 1 and 6(2.0%) in group 2 who stayed in the 
hospital for more than 10 days. But these results were not statistically significant. The 
analysis revealed a trend towards lesser hospital stay in the > 3-5 days categories, 
though not statistically significant. 
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Secondary outcomes: 
Table 17:Rate  of readmission 
Readmission Group 1 Group 2 Total P value 
Yes 4(1.3%) 3(1.0%) 7(1.2%) 1.000 
No 296(98.7%) 291(99.0%) 587(98.8%) 
 
Figure10 :  Rate of readmission 
 
The  rate of readmission into CMCH was low.There were totally only  7 women who  
required readmission,4(1.3%) from group 1 and 3(1%) from group 2. 
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Indication for readmission 
Table18 : Indication for readmission 
Indication  for readmission Group 1 Group 2 Total P value 
UTI 2(40.0%) 1(33.2%) 3(37.5%)  
 
0.554 
Endometritis 1(20.0%) 0 1(12.5%) 
Wound infection 0 1(33.2%) 1(12.5%) 
Others 0 1(33.2%) 1(12.5%) 
Figure11: Reason for readmission 
 
The indications for readmission were analysed in the study population, there 
were,3(37.5%) patients got readmitted for UTI,2 (40%) in group 1 and 1(33.3%) 
group 2. There was 1(20%) patient  group 1 who was readmitted for endometritis. 
There was 1(33.3%) in group 2 who was readmitted for SSI and 1(33.3%) with breast 
abscess in group 2(others category). 
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Allergic reaction to the study antibiotics: 
Table 19: Allergic reaction to the study drug 
Allergic  
reaction 
Group 1 Group 2 Total P value 
Yes 0 1(0.3%) 1  
1.000 
No 302 295(99.7%) 597 
 
Figure 12: Allergic reaction to the drugs:
 
In the study there was 1(0.3%) patient with  probable allergic reaction in group 2.No 
allergic reactions were noted in group 1 . This was not found to be significant. 
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Multivariate analysis of the primary outcome 
Table 13: Surgical site infection  
Variables  
 Intervention 
P value Extended Spectrum 
(n=11) 
Narrow Spectrum 
(n=16) 
Administration of antibiotics    
15 – 30 min 4 (36.4) 7 (63.6)  
30 – 1 Hr 4 (44.4) 5 (55.6)  
>1 Hrs 3 (42.9) 4 (57.1) 0.927 
Gravidity    
Primigravidae 3 (21.4) 11 (78.6)  
Multigravidae 8 (61.5) 5 (38.5) 0.034 
Antenatal risk factors    
HTN - 1 (100.0)  
GDM 2 (50.0) 2 (50.0)  
Hypothyroid - 1 (100.0) 0.472 
Preoperative haemoglobin    
>11gm (%) 10 (40.0) 15 (60.0)  
7 – 10gm (%) 1 (50.0) 1 (50.0) 1.000 
<7 gm (%)    
BMI    
<18.5 Kg/m
2
 - -  
18.5 – 24.9 Kg/m2 4 (44.4) 5 (55.6)  
25 – 29.9 Kg/m2 3 (27.3) 8 (72.7)  
>30 Kg/m
2
 3 (60.0) 2 (40.0) 0.438 
Duration of PROM    
<6 Hrs 1 (50.0) 1 (50.0)  
6 – 12 Hrs 3 (42.9) 4 (57.1)  
13 – 18 Hrs 2 (40.0) 3 (60.0) 0.971 
>24 Hrs - -  
Type of Cesarian  delivery    
Elective 5 (55.6) 4 (44.4) 0.320 
Emergency 6 (40.0) 11 (64.7)  
Blood Loss    
<500 ml 9 (37.5) 15 (62.5)  
600 – 1000 ml 2 (66.7) 1 (33.3) 0.549 
1100 – 2000 ml - -  
Length of  hospital stay    
3 – 5 days 10 (47.6) 11 (52.4)  
6 – 10 days 1 (20.0) 4 (80.0)  
>10 days - 1 (100.0) 0.370 
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Table 13:Endometritis 
Variables 
 Intervention P value 
Extended Spectrum 
(n=5) 
Narrow Spectrum 
(n=17) 
Administration of antibiotics    
15 – 30 min - 5 (100.0)  
30 – 1 Hr 4 (40.0) 6 (60.0)  
>1 Hrs 1 (14.3) 6 (85.7) 0.178 
Gravidity    
Primigravidae 1 (11.1) 8 (88.9)  
Multigravidae 4 (30.8) 9 (69.2) 0.360 
Antenatal risk factors    
HTN 1 (50.0) 1 (50.0)  
GDM 1 (33.3) 2 (66.7)  
Hypothyroid - 1 (100.0)  
Others 1 (50.0) 1 (50.0) 0.828 
Preoperative haemoglobin    
>11gm (%) 5 (23.8) 16 76.2)  
7 – 10gm (%) - 1 (100.0) 1.000 
<7 gm (%) - -  
BMI    
<18.5 Kg/m
2
 - 1 (100.0)  
18.5 – 24.9 Kg/m2 - 6 (100.0)  
25 – 29.9 Kg/m2 4 (50.0) 4 (50.0)  
>30 Kg/m
2
 1 (16.7) 5 (83.3) 0.146 
Duration of PROM    
<6 Hrs 1 (50.0) 1 (50.0)  
6 – 12 Hrs - 3 (100.0)  
13 – 18 Hrs 2 (50.0) 2 (50.0)  
>24 Hrs - 2 (100.0) 0.329 
Type of Cesarian delivery    
Elective 1 (12.5) 7 (87.5) 0.387 
Emergency 4 (28.6) 10(71.4)  
Blood Loss    
<500 ml 2 (16.7) 10(83.3)  
600 – 1000 ml 3 (30.0) 7 (70.0) 0.624 
1100 – 2000 ml - -  
Length of hospital stay    
3 – 5 days 3 (42.9) 4 (57.1)  
6 – 10 days 2 (16.7) 10 (83.3)  
>10 days - 3 (100.0) 0.253 
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Table 14:Urinary tract infection: 
Variables 
 Intervention P value 
Extended Spectrum 
(n=5) 
Narrow Spectrum 
(n=2) 
Administration of antibiotics    
15 – 30 min - 1 (100.0)  
30 – 1 Hr 3 (100.0) -  
>1 Hrs 2 (66.7) 1 (33.3) 0.155 
Gravidity    
Primigravidae 2 (66.7) 1 (33.3)  
Multigravidae 3 (75.0) 1 (25.0) 1.000 
Antenatal risk factors    
HTN - -  
GDM 2 (100.0) -  
Hypothyroid - -  
Others - - - 
Preoperative haemoglobin    
>11gm (%) 5 (71.4) 2 (28.6)  
7 – 10gm (%) - -  
<7 gm (%) - - - 
BMI    
<18.5 Kg/m
2
 - -  
18.5 – 24.9 Kg/m2 3 (100.0) -  
25 – 29.9 Kg/m2 2 (100.0) -  
>30 Kg/m
2
 - 2 (100.0) 0.030 
Duration of PROM    
<6 Hrs - -  
6 – 12 Hrs 1 (100.0) -  
13 – 18 Hrs 1 (50.0) 1 (50.0)  
>24 Hrs - - 1.000 
Type of Cesarian Section    
Elective 3 (75.0) 1 (25.0)  
Emergency 2 (66.7) 1 (33.3) 0.809 
Blood Loss    
<500 ml 4 (80.0) 1 (20.0)  
600 – 1000 ml 1 (50.0) 1 (50.0) 1.000 
1100 – 2000 ml - -  
Length of hospital stay    
3 – 5 days 3 (75.0) 1 (25.0)  
6 – 10 days 2 (66.7) 1 (33.3) 1.000 
>10 days - -  
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Table 15:  Cross analysis  on length of hospital stay for 6-10days and >10 days 
Variables Yes No P value 
Endometrtis 15(68.2%) 55(9.6%) 0.000 
Surgical site infections 6(22.2%) 60(10.7%) 0.063 
UTI 3(42.9%) 68(11.5%) 0.011 
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DISCUSSION 
 
In this study, which was done to compare the effect of adding extended spectrum 
antibiotics to the regular narrow spectrum antibiotics as prophylaxis at CD, the sample 
size of 1998 could not be completed within the time frame. The enrollment was 
stopped on July 30th for analysis.  
 According to Lomas et al, without antibiotic prophylaxis ,the rate of endometritis was 
reported as 20-85% and the rate of SSI was 25%(100).In the Cochrane review 
2014,the review found that there was  60% reduction in endometritis and SSI ,70% 
reduction in serious maternal infectious complication when prophylactic antibiotic 
was given compared with  placebo(6).According to the  ACOG,NICE guidelines, 
WHO,SOGC and the Swedish society of Obstetrics and Gynaecology,  the 
recommendation was that first generation cephalosporins be used as prophylaxis and 
that it should be administered 60 minutes prior to skin incision , the dose to be 
doubled if the patient was obese(7,92,101). Where  narrow spectrum antibiotic 
(Inj.Cefazolin) was used, the rate of endometritis was found to be 23%. When 
extended spectrum antibiotic (Inj.Azithromycin ) was added to the narrow spectrum as 
prophylaxis, the rate of endometritis was decreased to 2.3%.  In the studies done by 
O‟leary, Pitt et al, Meyer et al,Andrews et al , with the addition of extended  spectrum  
antibiotic (eg. Azithromycin, Metronidazole, Gentamycin), there was a significant 30 
to 60% reduction in post CD infectious morbidity , a decrease in  the length of  
hospital stay and  the cost with the use.(103) 
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In the study by Tita et al, in the year2008,it was found that there was a significant 
reduction in endometrtis, SSI, urinary tract infection and length of hospital stay after 
adding extended spectrum antibiotic(Azithromycin) as prophylaxis at CD(102–104).In 
another cohort study done by Tita et al ,done over 3 consecutive time periods ,with the 
addition of Inj.Azithromycin or oral Azithromycin to Inj. Cefazolin as prophylaxis, it 
resulted in a significant reduction in wound infection(P<0.02) and 
endometritis(P<0.001). 
There have been no studies comparing the outcomes when extended spectrum 
antibiotic was used along with narrow spectrum antibiotic in an RCT. 
In the present study, which compared the addition of extended spectrum antibiotic  
Inj.Azithromycin to Inj.Cefazolin, with In. Cefazolin alone, the  main infectious 
morbidity , represented by the primary outcomes of endometritis ,SSI ,and UTI were 
found to have reduced from 5.8% ,5.5% ,5% respectively with narrow spectrum 
antibiotic to  3.7%, 4.6% and 38.5.0% respectively, with extended spectrum 
antibiotics. This was not found to be statistically significant. 
When the outcome of endometritis alone was considered, it was found that there were 
a total of 3.7% women with evidence of endometriosis. In the group who had 
extended spectrum Azithromycin (group 1) there were 1.7%, as compared to the 
narrow spectrum group (group 2), which had 5.8% with endometritis.. There was 
statistically significant reduction (p value of 0.009) of evidence of endometritis with 
extended spectrum antibiotic in the univariate analysis, which was then found 
insignificant in the multivariate analysis. This was similar to the study done by 
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Andrew et al and Tita et al(56,102). But, the multivariate analysis did not reveal 
statistical significance in the present study. This could be due to the small sample size, 
and once the sample size is completed, these results could be different. 
With the primary outcome of SSI, the incidence (as shown in Table 14) was 4.6% , of 
which group 1 had 3.7% and group 2 had 5.5%.  this was not statistically significant  
as well, though the rate of SSI showed a trend towards lesser incidence of SSI with 
extended spectrum antibiotics. This finding was again similar to the study  done by 
Andrew et al and  Tita et al(56,10). 
 As far as UTI was considered, the incidence of urinary tract infection(UTI)  (as 
shown in Table 15),  was  5(38.5%) in group 1 and 2(5%) in group 2. The incidence of 
UTI in group 2  appeared to be less when compared to group 1, even though it was not 
statistically .Inj.Azithromycin was not protective against UTI. 
When length of hospital stay was analysed, it was found that (as in Table 16)in the 
present study  , duration of stay less than 5 days were the same in both groups, 
whereas it was 9.3% in group 1 and 11.8% in group 2 for those who stayed in the 
hospital for 6-10days. For those patients who stayed for more than 10 days, there were 
0.7% in group 1 and 2% in group 2.(P-0.139). Though the number of days of hospital 
stay seemed to be longer in group 2,  these results were  again not statistically 
significant. 
The rate of readmission into the same institution, which was an indirect marker for 
infectious morbidity in the long run, (as shown in Table 17), was very low.  There 
were totally only  7 women who  required readmission,4(1.3%) from group 1 and 
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3(1%) from group 2.These results were not statistically significant(P value-1.000). 
But, there could have been admissions or out patient visits to other Doctors or Clinics 
elsewhere by the patients, which could not be ascertained in this study. 
There were no maternal deaths due to sepsis or other infectious morbidity in the study. 
All considered, even though endometritis was significantly lower in the extended 
spectrum group, when multivatraite analysis was carried out, this was not found 
significant ,as was shown in other studies by Tita et al and  Andrew  et al. 
Similarly, the other main infectious morbidities that were studied in the present trial, 
SSI and UTI, did not show any significant difference with the addition of extended 
spectrum antibiotic, as prophylaxis. 
The reason for this insignificance, could be because the sample size was not reached, 
more numbers would be needed to show statistical difference. 
When assessing the safety profiles of both groups, allergic reaction to the study 
antibiotics (as shown in Table 19) ,there was only 1 patient with probable  allergic 
reaction in group 2.There were no allergic reactions  noted  in group 1 . This was not 
found to be significant (P value-1.000).  
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LIMITATION 
In the Christian Medical College Hospital which is a tertiary level hospital,  there 
were 14,276 deliveries in the year 2014. The  number of  CDs were 3985 and the CD 
rate was  29%.In spite of the large number of CDs that are performed, adequate 
numbers could not be included into the study, as dedicated research personnel were 
not available for the study for recruiting and detailed follow up. 
About 25 patients were lost to follow up due to various reasons - inability to reach 
them due their wrong contact number given at the time of randomisation . This could 
have been avoided if more care was taken to get information. 
Variables such as haemoglobin evaluation was not done preoperatively or in third 
trimester, which would have been a more accurate way of assessing the HB status of 
the patients . 
BMI calculated did not necessarily indicate pre pregnancy or early pregnancy BMI 
which is a better indicator of adverse pregnancy outcomes like SSI. Many patients had 
their first antenatal check up in CMC in their 3
rd
 trimester.  
The other draw back was that many primary and secondary outcomes were not 
statistically significant because the target sample size was not reached.  
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CONCLUSION 
1. The primary objective was to assess incidence of endometritis, SSI, UTI, and 
length of hospital stay . In the present study, the conclusions were the following : 
 The rate of endometritis reduction was statistically significant (p value of 
0.009)   with extended spectrum antibiotic in the univariate analysis, which was 
then found insignificant in the multivariate analysis. 
 Similarly, the incidence of SSI was significantly less in extended spectrum 
antibiotic, with univariate   analysis, but with multivariate analysis, was not 
statistically significant.  
 The incidence of UTI was more in the extended spectrum antibiotics group, 
when compared to the narrow spectrum antibiotic group, but was not found to 
be statistically significant. 
 The length of hospital stay of more than 6-10 days and more than 10 days were 
less in the extended spectrum antibiotic group, when compared with the narrow 
spectrum antibiotic group, but was not found to be  statistically significant.  
2. There was no allergic reaction  to extended spectrum antibiotic ,hence it can be 
concluded that it can be safely administered. 
3. The rate of re admissions were more in the extended spectrum group, when 
compared with the narrow spectrum antibiotic group .This was not found to be  
statistically significant.  
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ANNEXURES 
 
Department of Obstetrics And Gynaecology  
       Christian Medical College, Vellore  
A Double blind, randomised controlled trial  comparing  the effect of extended 
spectrum antibiotics with narrow spectrum antibiotic , for prophylaxis in Cesarean 
delivery.  
                        Information sheet 
You are requested to participate in a study , comparing  the benefits of antibiotics 
administered during Caesarean delivery and their effect on the mother and baby. At 
present, a single dose of antibiotic (Cefazolin) is routinely administered to the mother, 
half an hour prior to the Caesarean, according to the international recommendations, 
in order to reduce uterine infections after delivery. There is recent  evidence 
suggesting that addition of a second antibiotic (Azithromycin) will reduce the 
incidence of infection further. In this study, a comparison will be made between the 
two regimens of prophylactic antibiotics.  
Cefazolin controls infection caused by limited number of organisms. 
What happens if the Azithromycin is given along with Cefazolin? 
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Azithromycin, due to its longer duration of action, achieves higher concentrations in 
the tissues.  In addition, transfer to the baby is less than other antibiotics commonly 
used for this indication. 
If you take part what will you have to do? 
Both groups in the study will receive the Injection Cefazolin as per routine practice. 
The second group will receive Inj. Azithromycin in addition. In order to blind the 
participants and the doctors as to what treatment is being  received by the patient, 
those who are not receiving the second antibiotic will receive a placebo (a similar 
looking injection which has no antibiotic value) 
The treatment that you will be receiving will be decided by a computer programme 
and will be revealed only at the end of the study. 
You will continue to receive routine care as per the standard hospital protocols. You 
will be expected to come for a review to the hospital, 6 weeks after the Caesarean 
section ,for  a routine postnatal check up. At the start of  the study, in the ward and the 
6 weeks postnatal visit, you will be asked questions about  your  wellbeing .No 
additional procedure or blood tests will be done for this study, unless you or your 
baby develop infections. 
If at any time you experience fever or redness or any discharge from the surgery site 
or any wound gaping, you will be expected to report this to your unit doctor. In case 
there is need for additional information by the doctors  conducting the study,they will 
contact you. 
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 Can you withdraw from this study after it starts? 
Your participation in this study is entirely voluntary and you are also free to decide to 
withdraw from this study. If you do so, this will not affect your usual treatment at this 
hospital in any way .In addition, if you experience any serious side effects, you will be 
given appropriate treatment. 
What will happen if you develop any study related injury? 
We do not expect any injury to happen to you but if you do develop any side effects or 
problem due to the drug or drug administered as part of the study, this will be treated 
free. We are unable to provide any monetary compensation, however. 
Will you have to pay for the study tablets? 
Cefazolin is the drug  routinely  used as antibiotic for the Caesarean delivery which 
you need to buy anyways. Inj. Azithromycin and the placebo injection will be 
provided from the study fund by the hospital. 
What happens after the study is over? 
Since these drugs are given only as a prophylactic treatment, after the study is over 
you will not get any further benefit other than the protection against infection you 
have already got from such treatment. 
Will your personal details be kept confidential? 
The results of this study will be published in a medical journal but you will not be 
identified by name in any publication or presentation of the results. However, your 
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medical notes may be reviewed by people associated with the study, without your 
additional permission, should you decide to participate in this study. 
CONSENT TO TAKE PART IN A CLINICAL TRIAL 
Study Title: Prophylactic antibiotics in Caesarean section(PACS-study) 
Study Number: 
Participants‟ name: 
Date of Birth/Age (in years): 
I____________________________________________________________________
____________________, daughter/wife of__________________________ 
(Please tick boxes) 
Declare that I have read the information sheet provide to me regarding this study and 
have clarified any doubts that I had. [ ] 
I also understand that my participation in this study is entirely voluntary and that I am 
free to withdraw permission to continue to participate at any time without affecting 
my usual treatment or my legal rights [ ] 
I also understand that neither I, nor my doctors, will have any choice or knowledge of 
what drug is being administered. [ ] 
I understand that I will receive free treatment for any study related injury or adverse 
event but I will not receive other financial compensation [ ] 
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I understand that the study staff and institutional ethics committee members will not 
need my permission to look at my health records even if I withdraw from the trial. I 
agree to this access [ ] 
I understand that my identity will not be revealed in any information released to third 
parties or published 
I voluntarily agree to take part in this study. 
Name: 
Signature or thumb print: 
Date: 
Name of witness                 : 
Signature or thumb print  : 
Relation to participant       : 
Date:  
Signature of the Investigator : 
Date                                                : 
Study Investigator „s Name     : 
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                        Profoma Sheet 
1.Name:                                 Age:         Hospital no:                               Date: 
Address   :                             Gestational Age:                                       Ph No: 
2.Serial no:                                     
3.Time of starting antibiotics: 
4.No: of cefazolin dose:1.1                2.2                                3.>2 
5.Indication for additional dose of cefazolin: 1.Increased duration of sugery  2.Morbid 
obesity  
6.Time of  skin incision  : 
7.Gravidity -       1.Primigravida             2.Multigravida 
8.Antenatal risk factors:           1.HTN                 2.DM                      3. Hypothyroid              
4.Others 
9.Preoperative Hemoglobin:        1.>11gm%        2.7-10.9gm%       3.<7gm% 
10.BMI:    1.<18.5kg/m2               2. 18.5-24.9kg/m2               3.25-29.9kg/m2 
4.>30kg/m2                   5.>40kg/m2 
11.Duraation of PROM: 1.<6hrs     2.6-12hrs    3.13-18hrs 
12.Type of Cesarean section:       1.Elective   2.Emergency      3.Semi emergency 
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13.Indication forEmergency cesarean section:     1.NRFS      2.Abnormal lie in labor     
3.Prev LSCS  with NRFS      4.IUGR       5.Labor dystocia      5.Failed Induction 
6.Others. 
14  Indication for Semi emergency section:     1.Previous LSCS not willing for VBAC 
in Labor    2.Posted for elective LSCS comes in labor 3.others 
15.  Indication for Elective caesarean section:     1.Previous LSCS not willing for 
VBAC  2.Breech presentation  3.Twins with first twin non vertex   4.IUGR with 
abnormal dopplers 5.others 
16.  Duration of Surgery:     1.1hr       2.1-2hrs          3.>2hrs 
17.  Blood Loss:  1.<500ml     2.600-1000ml      3.1100-2000ml 
18.  Intraoperative Complication:    1.PPH          2.Bladder injury 3.Extension of 
uterine incision 
19.Blood Transfusion:       1.Yes      2.No 
20.No: of Blood transfused:    1.1-2    2.3-4     3.>5 
21.No: of Blood products transfused: 
 
Postoperative monitoring in the Ward 
1.1No: of days of hospital stay: 
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2.Evidence of Endometritis(Temp->100.4F or uterine tenderness or foul smelling 
Lochia) :   1.Yes      2.No 
3.Febrile Morbidity(100.4F in 2 occasion 6 hrs apart without cause):1.Yes           2.No 
4.Surgical site infection:1.Yes                 2.No 
5.Need for therapeutic antibiotics:        1.Yes          2.No 
6.Indication for therapeutic antibiotics:   1.UTI       2.Endometritis 3.Surgical site 
infection 4.others 
7.Allergic reaction to study drugs:     1.Yes        2.No 
 
Discharge to 42days of postpartum: 
1.Readmission : 1.Yes             2.No  
2.Need for antibiotics:     1.Yes          2.No 
3.Number of hospital visit from the time of discharge to 42days postpartum:      1.Nil           
2.1-2              3.2-3 
4.Reason for Readmission: 1.UTI      2.Endometriti       3.baby„s sake               
4.surgical site infection         5.others 
5.Length of hospital stay :    1.2-3days       2.4-7days      3.>7days 
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DATA SHEET 
slno hno age 
Ges 
age date 
Anti 
bio gravid 
Ante 
risk Riskoth 
Pre 
hemo bmi 
Dur 
prom cesarean 
Eme 
rcs 
Eme 
roth ieses semioth 
1 420683f 25 37 2/24/2015 1 2 
  
1 3 
 
3 
  
1  
2 094784G 27 37.1 2/24/2015 1 2 
  
1 2 2 2 5 
 
  
3 030736g 17 40.3 2/24/2015 2 1 
  
1 4 2 2 3 
 
  
4 163496G 25 37.3 2/25/2015 2 2 2 
 
1 
  
1 
  
  
5 059686G 28 39.2 2/25/2015 2 2 
  
2 
  
1 
  
  
6 045781f 30 37.6 2/25/2015 2 2 
  
1 
  
1 
  
  
7 120976g 29 40 2/25/2015 2 1 2 
 
1 3 2 2 3 
 
  
8 150008g 25 39.3 2/25/2015 2 2 
  
1 2 
 
3 
  
1  
9 397323f 23 37.1 2/26/2015 1 2 
  
1 3 3 2 4 
 
  
10 917600f 20 39.1 2/25/2015 2 2 
  
1 3 2 2 1 
 
  
11 598638d 26 40.4 2/26/2015 1 2 
  
1 
 
2 2 4 
 
  
12 169927f 20 39.1 3/2/2015 1 2 
  
2 3 2 2 1 
 
  
13 100328f 26 40 3/2/2015 2 2 
  
2 3 
 
3 
  
1  
14 032987g 27 38.4 3/2/2015 2 1 2 
 
1 3 
 
3 
  
2  
15 296139f 32 39.1 3/2/2015 2 2 
  
1 2 
 
3 
  
1  
16 096827f 27 40.6 2/26/2015 2 1 1 
 
1 4 2 2 4 
 
  
17 805149d 25 35.6 2/26/2015 
     
1 
    
  
18 5841136 29 38.3 2/27/2015 2 2 2 
 
1 4 
 
3 
  
1  
19 161792g 24 38.3 2/28/2015 2 1 
  
1 2 1 3 
  
2  
20 667167c 
  
2/8/2015 
     
4 
    
  
21 117391g 22 41.1 2/28/2015 2 2 
  
1 4 2 2 4 
 
  
22 161631g 36 40.1 3/1/2015 1 1 
  
1 3 2 2 1 
 
  
23 381742d 36 37.5 3/1/2015 2 1 4 
 
1 4 2 2 4 
 
  
24 049612g 29 40.3 3/1/2015 1 1 
  
1 3 2 2 1 
 
  
25 023158g 25 40.4 3/2/2015 1 1 
  
1 2 3 2 1 
 
  
26 133355g 17 39.4 3/2/2015 2 1 
  
1 3 1 1 
  
  
27 016795g 30 40.4 3/2/2015 2 1 
  
1 3 2 2 2 
 
  
28 042351g 29 38.2 3/2/2015 3 2 
  
2 3 
 
2 5 
 
  
29 318656d 31 38.6 3/3/2015 2 2 2 
 
1 
 
1 1 
  
  
30 090257g 32 40.4 3/3/2015 2 2 
  
1 3 2 1 1 
 
  
31 020213g 23 37.2 3/3/2015 2 1 1 
  
3 
 
2 2 
 
  
32 613108f 30 38.5 3/5/2015 2 2 
  
1 4 3 2 3 
 
  
33 719054f 25 37.2 3/3/2015 2 2 2 
 
1 2 1 2 1 
 
  
34 156406f 26 38.5 3/4/2015 2 2 
  
1 4 
 
1 
  
  
35 096577g 26 38 3/4/2015 
 
2 
  
2 
  
1 
  
  
36 454471f 30 38.3 3/4/2015 2 2 
  
1 2 
 
1 
  
  
37 074188g 30 37.2 3/4/2015 2 2 
  
1 2 
 
1 
  
  
38 188564f 24 37.4 3/4/2015 1 2 
  
2 1 
 
1 
  
  
39 018159f 24 38 3/4/2015 3 2 
  
1 
  
1 
  
  
40 870562d 24 38.5 3/4/2015 3 2 
  
2 
  
1 
  
  
41 004983g 20 39.5 3/5/2015 1 1 
  
1 4 3 2 4 
 
  
42 485632f 30 38.4 3/5/2015 2 2 
  
1 4 
 
3 
  
2  
43 835759f 19 39.2 3/8/2015 2 1 
  
1 3 
 
2 2 
 
  
44 154474g 20 39.1 3/8/2015 2 1 3 
 
1 2 
 
2 1 
 
  
45 927068d 33 37.4 3/10/2015 1 1 2 
 
1 3 2 2 4 
 
  
46 938971f 25 40.4 3/6/2015 2 1 
  
1 4 3 2 4 
 
  
47 392970f 23 39.6 3/6/2015 2 2 
  
2 3 3 2 4 
 
  
48 017169f 26 39.3 3/6/2015 2 2 
  
2 3 2 2 1 
 
  
49 317509f 27 40.3 3/6/2015 2 2 
  
1 4 1 2 5 
 
  
50 021431g 21 38.5 3/6/2015 3 1 
  
2 2 
 
1 
  
  
51 061317g 27 39.1 3/6/2015 2 1 4 
 
1 4 1 2 1 
 
  
52 045510g 25 40.5 3/6/2015 2 1 
  
1 3 3 2 3 
 
  
53 451668f 36 38.3 3/7/2015 1 2 
  
1 4 2 2 1 
 
  
54 026766g 33 39.2 3/7/2015 1 1 2 
 
1 4 2 2 1 
 
  
55 086006g 23 37.3 3/7/2015 2 2 
  
1 2 
 
3 
  
1  
56 671761d 24 38.1 3/9/2015 3 2 
  
2 4 
 
1 
  
  
57 071448g 24 38.1 3/9/2015 3 2 1 
 
1 4 
 
1 
  
  
58 194809f 22 40.6 3/9/2015 1 2 
  
1 4 
 
3 
  
2  
59 136169g 25 37.1 3/9/2015 2 2 
  
1 3 
 
3 
  
3  
60 938987f 29 40.5 3/9/2015 2 1 
  
1 2 2 2 3 
 
  
61 938993f 21 37.2 3/10/2015 2 1 1 
 
2 4 2 2 5 
 
  
 123 
 
62 174792g 20 38.5 3/10/2015 2 1 
  
1 
 
2 2 1 
 
  
63 065860g 36 38.1 3/12/2015 3 1 3 
 
1 4 
 
3 
  
1  
64 566799d 33 39.4 3/9/2015 2 2 
  
1 3 2 3 
  
1  
65 507747a 29 37.6 3/10/2015 1 2 2 
 
1 2 1 2 1 
 
  
66 365474d 28 39 3/10/2015 3 2 
  
1 3 
 
1 
  
  
67 664597d 35 38 3/11/2015 3 2 2 
 
1 3 
 
3 
  
1  
68 038763f 31 38.3 3/11/2015 3 2 
  
2 2 
 
1 
  
  
69 167083f 27 38.3 3/11/2015 3 2 
  
1 4 
 
1 
  
  
70 365643f 26 38.6 3/11/2015 3 2 
  
1 3 1 1 
  
1  
71 211863f 28 38.2 3/11/2015 3 2 
  
1 2 
 
1 
  
  
72 066896f 23 37.1 3/13/2015 3 2 
  
1 4 
 
1 
  
  
73 439464f 25 39.5 3/11/2015 1 1 
  
1 2 2 2 1 
 
  
74 928636f 21 37.2 3/11/2015 1 1 
  
1 
 
3 2 1 
 
  
75 393461F 28 40 3/13/2015 2 2 
  
1 3 3 2 3 
 
  
76 138820G 23 39 3/12/2015 1 1 
  
1 4 2 2 1 
 
  
77 497652d 30 37.2 3/21/2015 3 2 
  
1 3 
 
1 
  
  
78 112160g 27 40 3/12/2015 2 1 3 
 
1 4 3 2 4 
 
  
79 168791g 25 39.4 3/12/2015 2 1 
  
1 3 2 2 4 
 
  
80 602501d 31 37.5 3/12/2015 2 1 4 
 
1 4 
 
3 
  
2  
81 614178d 30 38.1 3/12/2015 3 2 2 
 
1 4 
 
1 
  
  
82 100053g 31 38.2 3/12/2015 2 2 
  
1 2 
 
1 
  
  
83 040567g 28 37 3/13/2015 2 1 1 
 
1 4 2 2 4 
 
  
84 158983g 26 39 3/13/2015 1 1 4 
 
1 3 2 2 1 
 
  
85 068587g 24 39 3/13/2015 2 1 4 
 
1 3 2 2 3 
 
  
86 175726g 25 39 3/14/2015 1 1 
  
1 2 3 2 1 
 
  
87 128457g 23 37.5 3/13/2015 1 1 
  
1 3 1 2 1 
 
  
88 504877f 32 38.2 3/14/2015 3 2 1 
 
1 2 
 
1 
  
  
89 232859f 23 38 3/14/2015 3 2 
  
1 3 
 
1 
  
  
90 143024g 29 39 3/14/2015 2 2 2 
 
1 4 
 
2 
  
1  
91 940434f 24 39.1 3/16/2015 2 2 4 
 
2 2 
 
3 1 
 
  
92 024013g 29 39.1 3/16/2015 1 1 2 
 
1 3 1 2 1 
 
  
93 015243g 28 41 3/17/2015 2 2 
  
1 2 2 2 4 
 
  
94 940433f 25 40.4 3/17/2015 2 1 
  
2 3 3 2 4 
 
  
95 940447f 25 37.5 3/19/2015 1 2 1 
 
2 4 2 2 1 
 
  
96 680771f 28 37.2 3/19/2015 2 1 1 
 
1 4 
 
2 
  
2  
97 940446f 20 37.6 3/19/2015 2 1 1 
 
1 
 
3 2 4 
 
  
98 717750f 31 39.5 3/22/2015 2 2 
  
1 2 
 
2 5 
 
  
99 175293g 31 38.1 3/25/2015 2 2 4 
 
1 4 
 
1 
  
  
100 084079g 19 40.4 3/22/2015 1 1 4 
 
1 2 2 2 1 
 
  
101 860294d 23 37.1 3/18/2015 3 2 4 
 
2 2 
 
1 
  
  
102 293491f 25 37.1 3/18/2015 3 2 2 
 
2 3 
 
1 
  
  
103 90307d 24 38.1 3/18/2015 2 2 
  
1 3 
 
1 
  
  
104 052716f 32 37.2 3/18/2015 3 2 
  
1 3 
 
1 
  
  
105 877886f 19 37 3/18/2015 3 1 
  
1 1 1 
   
  
106 044446g 19 39.4 3/18/2015 1 1 4 
 
1 4 2 2 1 
 
  
107 064306g 25 39 3/18/2015 1 1 
  
1 3 3 2 1 
 
  
108 168506g 24 39 3/18/2015 1 1 
  
1 3 2 2 1 
 
  
109 940442f 28 40.3 3/18/2015 1 1 
  
1 4 2 2 1 
 
  
110 536668d 27 39.2 3/18/2015 1 2 1 
 
1 3 2 2 1 
 
  
111 056025g 33 37.3 3/19/2015 2 2 1 
 
1 4 
 
3 
  
1  
112 085328g 24 38.5 3/20/2015 1 1 
  
1 3 1 2 1 
 
  
113 043230g 31 39.2 3/20/2015 1 1 
  
1 2 1 2 1 
 
  
114 079991g 26 37.3 3/20/2015 2 2 1 
 
2 1 2 2 3 
 
  
115 082420g 21 38.4 3/20/2015 1 1 
  
1 3 1 2 1 
 
  
116 111444g 19 37.6 3/21/2015 1 1 1 
 
1 4 1 2 1 
 
  
117 165169g 22 38.1 3/21/2015 1 1 
  
1 3 1 2 1 
 
  
118 116626g 29 40.3 3/21/2015 2 1 
  
1 3 3 2 4 
 
  
119 077391g 25 37.6 3/20/2015 2 1 4 
 
2 4 
 
2 4 
 
  
120 546074d 26 39.1 3/21/2015 3 2 2 
 
1 4 
 
1 
  
  
121 161432g 32 39.1 3/24/2015 3 2 
  
1 4 
 
1 
  
  
122 160324g 23 40.1 3/24/2015 1 2 4 
 
1 3 1 2 1 
 
  
123 073152g 24 38.4 3/24/2015 1 1 1 
 
2 4 3 2 1 
 
  
124 149697g 33 40.3 3/23/2015 2 1 2 
 
1 3 
 
2 4 
 
  
125 043148g 31 39.6 3/26/2015 1 1 
  
1 4 2 2 1 
 
  
126 058065g 31 39.6 3/24/2015 1 1 2 
 
2 4 3 2 1 
 
  
127 
 
23 
            
  
128 131471g 25 37.5 3/24/2015 1 1 1 
 
1 4 2 2 1 
 
  
 124 
 
129 119589g 25 39.5 6/5/2015 
          
  
130 124755g 33 38.5 3/24/2015 1 1 2 
 
1 4 2 2 1 
 
  
131 323093f 18 40.3 3/25/2015 3 2 
  
1 2 
 
1 
  
  
132 101403g 29 38.6 3/25/2015 3 1 4 
 
2 3 
 
1 
  
  
133 117070g 20 39.5 3/25/2015 2 1 
  
1 2 3 2 4 
 
  
134 088440g 28 39.4 3/25/2015 3 1 
  
1 3 
 
1 
  
  
135 178303g 24 38.2 3/25/2015 3 1 4 
 
2 2 
 
1 
  
  
136 239112f 25 37.6 3/25/2015 3 2 
  
1 2 
 
1 
  
  
137 932508b 38 38.5 3/25/2015 2 1 1 
 
1 3 2 2 4 
 
  
138 
 
26 39 
           
  
139 089688g 29 38.6 3/25/2015 2 2 
  
2 3 
 
2 2 
 
  
140 126792g 31 40.2 3/25/2015 1 2 2 
 
1 3 2 2 1 
 
  
141 074556g 25 39.3 3/25/2015 2 2 
  
1 2 3 2 4 
 
  
142 174778g 25 40.2 3/25/2015 2 1 
  
1 2 3 2 1 
 
  
143 116489g 26 40.3 3/25/2015 1 1 
  
1 3 3 2 1 
 
  
144 755612f 25 37.3 3/25/2015 2 2 2 
 
1 3 
 
2 5 
 
  
145 201329b 30 39.5 3/26/2015 2 2 
  
2 3 
 
3 
  
1  
146 207723f 30 38.3 3/26/2015 2 2 
  
1 
  
1 
  
  
147 110618f 27 38.6 3/26/2015 1 2 2 
 
1 2 1 2 1 
 
  
148 375634f 22 40.1 3/26/2015 3 2 
  
1 3 
 
1 
  
  
149 189284g 22 40.3 3/26/2015 1 1 
  
1 2 2 
 
1 
 
  
150 076977d 39 38 3/26/2015 2 2 2 
 
1 3 
 
3 
  
1  
151 031515g 24 38.3 3/27/2015 2 1 1 
 
2 2 2 2 4 
 
  
152 627750f 37 38.2 3/27/2015 1 2 2 
 
2 4 
 
1 
  
  
153 940486f 20 35 3/26/2015 
          
  
154 073661g 25 37 3/27/2015 2 1 
  
1 2 
 
3 
  
2  
155 614562c 29 39 3/27/2015 3 2 2 
 
1 2 
 
1 
  
  
156 175707g 25 39.2 3/27/2015 1 1 
  
1 2 3 2 1 
 
  
157 940491f 25 40.1 3/28/2015 2 1 2 
pri mary 
infertility 1 2 3 2 3 
 
  
158 170418g 20 40.4 3/28/2015 2 2 
 
Rh 
negative 1 3 2 2 4 
 
  
159 
 
27 38 
           
  
160 655199f 27 37.1 3/28/2015 2 1 4 twins,IVF 2 3 
 
3 
  
3  
161 417042f 27 37.1 4/8/2015 3 2 2 
 
1 3 
 
1 
  
  
162 422781c 34 40.4 3/29/2015 1 2 
  
1 3 1 2 1 
 
  
163 898324d 30 38 3/28/2015 1 2 
  
1 1 
 
1 
  
  
164 802280f 22 39.2 3/29/2015 1 1 
  
1 2 2 2 1 
 
  
165 940499f 23 38.2 3/29/2015 1 2 4 Anemia 2 2 1 1 1 
 
  
166 317015f 
  
3/30/2015 1 2 
  
1 3 
 
3 
  
1  
167 049606g 23 40.3 3/30/2015 2 2 
  
1 2 3 2 4 
 
  
168 912606d 23 37.2 3/31/2015 2 2 4 twins 1 3 2 2 3 
 
  
169 858275c 34 38.3 3/31/2015 2 2 
   
3 1 3 
  
1  
170 384949f 21 39.6 3/31/2015 1 2 
  
1 2 1 2 1 
 
  
171 572840D 35 38 4/1/2015 1 2 
  
1 3 
 
1 
  
  
172 466420c 27 37.1 3/31/2015 1 2 2 
Chronic 
HTN 1 2 
 
3 
  
 
prev  
preterm 
LSCS in 
 labor 
173 879431d 31 37.2 4/1/2015 3 2 2 
 
1 3 
 
1 
  
  
174 073340g 28 37.2 4/8/2015 2 2 3 
 
1 2 
 
1 
  
  
175 141144g 26 38.6 3/31/2015 1 1 3 
Morbidly 
 obese 1 4 3 2 4 
 
  
176 549163d 27 37 4/1/2015 3 1 4 br asthma 1 2 
 
1 
  
 
placenta 
previa 
177 374112f 24 37.6 4/1/2015 3 2 3 
 
1 3 
 
1 
  
  
178 623007f 23 38.5 4/1/2015 3 2 
  
1 3 
 
1 
  
  
179 454214d 32 38.5 4/1/2015 3 2 
  
2 3 
 
1 
  
  
180 040029g 24 38.5 3/31/2015 2 1 1 
 
1 3 2 2 4 
 
  
181 024509f 33 38 4/2/2015 3 2 2 
 
1 2 
 
1 
  
  
182 
 
22 
            
  
183 051982g 27 38.3 4/8/2015 3 2 
  
2 3 
 
1 
  
  
184 727070f 36 37.2 4/2/2015 3 1 
  
2 2 
 
3 
  
 
IVF preg  
in early  
labor 
185 129210g 41 37.5 4/8/2015 3 2 2 
 
1 3 
 
1 
  
  
186 834851d 28 38.6 4/3/2015 3 2 
  
1 3 2 2 4 
 
  
187 165686g 31 40.3 4/7/2015 3 2 
  
2 3 3 
   
1  
 125 
 
188 090735g 28 37 4/8/2015 3 2 2 
 
1 3 
 
1 
  
  
189 067535g 32 40.3 ####### 2 1 1 
 
1 2 2 2 3 
 
  
190 
 
30 
            
  
191 180133g 28 40.5 4/9/2015 2 1 
  
1 2 2 2 4 
 
  
192 154146g 33 38 4/4/2015 1 2 
  
1 3 2 2 4 
 
  
193 062350g 21 39.4 5/4/2015 2 1 
  
1 2 2 2 3 
 
  
194 943537f 21 40.2 4/6/2015 2 1 
  
1 2 3 2 5 
Brow 
presentation   
195 081727f 28 38.1 4/8/2015 3 2 3 
 
1 2 
 
2 
  
  
196 099186g 26 40.5 4/7/2015 1 1 
  
1 2 2 2 1 
 
  
197 075496f 23 38 4/7/2015 2 2 
  
1 2 1 3 
  
2  
198 922189f 27 39.3 4/7/2015 2 1 2 
 
1 3 3 2 4 
 
  
199 031421g 26 39.2 4/7/2015 3 2 
  
1 3 
 
3 
  
1  
200 452968d 29 39 4/8/2015 3 2 
  
1 2 
 
1 
  
  
201 191429f 28 38.1 4/8/2015 2 2 
  
1 4 
 
3 
  
 
breech  
in labor 
202 073889g 23 39.2 4/10/2015 2 1 1 
 
1 4 2 2 3 
 
  
203 407074d 33 38 4/14/2015 3 2 
   
3 
 
1 
  
1  
204 174366g 30 40.4 4/11/2015 2 1 3 
 
1 3 3 2 3 
 
  
205 797821f 28 39.3 4/28/2015 1 1 2 
 
1 4 3 1 1 
 
  
206 099125g 33 37.6 4/10/2015 1 1 
  
1 4 2 2 1 
 
  
207 036312g 30 40.5 4/7/2015 1 1 2 
 
1 4 3 2 1 
 
  
208 095237g 32 40.1 4/14/2015 1 1 
  
1 4 1 2 1 
 
  
209 933173c 43 37 4/13/2015 2 2 1 
1,2,3, 
morbid  
obese 1 4 
 
1 
  
  
210 943563f 31 38.2 4/9/2015 2 2 4 
asthma, 
morbily  
obese 1 4 
 
1 
  
  
211 133246g 27 40.5 4/9/2015 2 1 2 
 
1 4 4 2 3 
 
  
212 474630f 27 40 4/9/2015 2 1 2 
 
1 4 3 2 4 
 
  
213 153802g 23 32 4/10/2015 
          
  
214 972875d 30 38.6 4/10/2015 3 2 2 
 
1 4 
 
1 
  
  
215 112637g 26 37.5 4/12/2015 2 1 3 
 
1 3 
 
3 
  
2  
216 489300d 30 37 4/12/2015 2 2 
  
1 3 1 3 
  
 
breech  
with  
prom 
217 074982g 23 38 4/13/2015 2 1 1 
 
1 3 3 2 3 
 
  
218 424690f 21 40.4 4/14/2015 1 2 
  
2 3 1 2 1 
 
  
219 401711f 23 38.6 4/14/2015 2 2 
  
1 2 
 
3 
  
1  
220 176897g 24 41 4/14/2015 1 1 
  
1 3 3 2 1 
 
  
221 174143g 28 37 4/15/2015 3 2 
  
1 3 
 
1 
  
  
222 928116d 29 38.4 4/15/2015 3 2 
  
1 3 
 
1 
  
  
223 836645c 30 39 4/15/2015 3 2 
  
1 3 
 
1 
  
  
224 979197d 25 38 4/15/2015 3 2 
  
2 2 
 
3 
  
 
placenta 
previa 
225 200080g 20 39.1 4/15/2015 1 2 
  
1 3 3 2 1 
 
  
226 038619g 23 38.6 4/15/2015 3 2 
  
1 3 
 
1 
  
  
227 943587f 32 38.6 4/15/2015 2 2 
  
1 4 
 
1 
  
  
228 886417g 27 37.1 4/15/2015 2 2 1 gdm 1 3 
 
1 
  
  
229 185004g 24 38.4 4/15/2015 3 2 
  
2 2 
 
1 
  
  
230 177988c 40 39.1 4/15/2015 3 2 
  
1 3 
 
1 
  
  
231 728729d 28 38 4/15/2015 3 2 2 
 
1 3 
 
1 
  
  
232 943590f 22 40 4/16/2015 1 1 
  
1 2 3 2 1 
 
  
233 470661f 32 37 4/16/2015 2 1 2 
 
2 3 
 
3 
  
 
twins  
with 
unfavour 
able 
cervix 
234 144935g 27 40.1 4/15/2015 2 1 
  
1 4 2 2 5 
brow 
presentation   
235 121131g 29 39.1 4/15/2015 1 2 2 
 
1 3 1 2 1 
 
  
236 323959d 29 39.3 4/17/2015 2 2 3 
 
1 3 3 2 4 
 
  
237 364006a 31 39.5 4/15/2015 2 2 3 gdm 2 4 3 2 4 
 
  
238 170226g 29 38.4 4/17/2015 1 1 
  
1 3 3 2 1 
 
  
239 parvina 29 40.4 4/16/2015 1 2 4 
 
2 3 1 2 1 
 
  
240 814546d 25 39.6 4/18/2015 1 1 
  
1 3 2 2 1 
 
  
241 yasmeen 31 38 4/21/2015 2 2 
  
2 2 1 3 
  
1  
 126 
 
242 206846g 23 37.5 4/21/2015 2 2 
  
1 3 
 
3 
  
1  
243 120980g 23 40.5 4/21/2015 2 1 
  
2 2 3 2 3 
 
  
244 230691d 31 38.1 4/27/2015 2 2 
  
2 3 
 
3 
  
1  
245 889353f 28 37.2 4/28/2015 2 2 2 HTN 1 4 3 2 4 
 
  
246 331805f 25 39.1 4/22/2015 2 2 2 
 
1 4 3 3 
  
2  
247 488162d 25 37.2 4/22/2015 2 1 1 
 
2 3 
 
3 
  
 
placenta 
praevia 
248 906368f 27 38.6 4/22/2015 3 2 2 
 
1 3 
 
1 
  
  
249 441319f 20 39.3 4/22/2015 3 2 
  
1 2 
 
1 
  
  
250 132900g 28 39 4/22/2015 2 2 
  
1 2 
 
1 
  
  
251 699900d 23 39 4/22/2015 3 2 
  
1 2 
 
1 
  
  
252 051127g 32 39.1 4/22/2015 3 2 2 
 
1 2 
 
1 
  
  
253 128338g 27 37.4 4/23/2015 2 1 
  
1 2 
 
3 
  
2  
254 469587f 20 37.2 4/23/2015 3 2 
  
1 2 
 
1 
  
  
255 301423f 27 37.2 4/22/2015 2 2 
  
1 2 
 
3 
  
2  
256 081193g 25 39.2 4/23/2015 2 2 1 
 
1 4 
 
1 
  
  
257 951221f 28 40.4 4/22/2015 2 1 
  
1 3 
 
2 3 
 
  
258 180604g 28 39.6 4/24/2015 1 2 2 
 
1 4 2 2 1 
 
  
259 593491a 28 39.6 4/24/2015 2 1 
  
1 3 3 2 3 
 
  
260 173092g 22 39.1 4/23/2015 1 1 
  
1 3 1 2 1 
 
  
261 926158f 26 37.4 4/24/2015 1 1 
  
1 2 1 2 1 
 
  
262 051707g 28 41 4/24/2015 2 1 
  
1 3 2 2 3 
 
  
263 951244f 22 37.2 4/25/2015 1 1 1 
 
2 3 
 
2 1 
 
  
264 422750d 33 37 4/24/2015 3 2 2 
 
1 3 
 
1 
  
  
265 208655g 29 39.6 4/24/2015 2 1 
  
2 3 
 
2 3 
 
  
266 572890d 33 38 4/24/2015 3 2 2 
 
1 3 
 
1 
  
  
267 185443g 27 39.3 
           
  
268 349487f 24 38 4/29/2015 3 2 
  
1 4 
 
1 
  
  
269 104899g 21 40.4 4/29/2015 3 2 
  
1 3 
 
1 
  
  
270 669138d 25 38 5/3/2015 2 2 
  
1 3 
 
1 
  
  
271 294932f 22 38.4 4/29/2015 2 2 
  
1 2 2 2 4 
 
  
272 379009f 26 39.4 4/26/2015 3 2 
  
1 3 
 
1 
  
  
273 089590f 34 39.3 4/28/2015 3 2 2 
 
1 2 
 
1 
  
  
274 207897g 26 40 4/28/2015 1 2 2 
 
1 3 2 2 1 
 
  
275 
 
24 
            
  
276 061747f 24 39.3 5/3/2015 2 2 
  
1 3 
 
1 
  
  
277 126523g 31 38.1 4/28/2015 3 2 2 
 
1 3 
 
1 
  
  
278 244922f 24 38.2 4/29/2015 3 2 
  
1 3 1 3 
  
1  
279 103921G 25 39.3 4/29/2015 3 2 
  
1 3 
 
1 
  
  
280 104684g 24 38.3 4/29/2015 2 1 
  
1 4 3 2 4 
 
  
281 183883g 28 37.4 5/2/2015 2 1 
  
1 3 3 2 3 
 
  
282 752913f 27 38.2 4/29/2015 2 2 1 
 
1 3 3 2 4 
 
  
283 410919d 29 39.2 4/29/2015 3 2 2 
 
1 3 
 
3 
  
3  
284 635955d 31 40.5 4/29/2015 2 2 
  
1 2 1 3 
  
1  
285 732061d 27 39 4/29/2015 3 2 
  
3 2 
 
1 
  
  
286 136343f 25 37.6 4/30/2015 3 2 
  
2 3 
 
1 
  
  
287 982863d 29 39.2 4/29/2015 3 2 
  
2 3 
 
1 
  
  
288 211546g 28 38.1 4/30/2015 3 2 
  
1 2 
 
1 
  
  
289 743359c 36 39 5/1/2015 3 2 
  
1 3 
 
1 
  
  
290 087889g 26 37.6 4/30/2015 2 1 
  
1 4 3 2 3 
 
  
291 150294g 27 39 4/29/2015 2 2 
  
2 3 3 2 4 
 
  
292 951851f 33 40.1 5/13/2015 3 2 
  
1 3 
 
1 
  
  
293 482932f 28 40 5/16/2015 2 2 2 
 
1 4 2 2 4 
 
  
294 
 
8 
            
  
295 125030g 28 37.4 5/13/2015 3 1 1 
 
1 1 
 
1 
  
  
296 100679g 30 39.6 5/5/2015 1 2 
  
2 2 1 2 1 
 
  
297 194927g 21 39.6 5/5/2015 1 2 
  
1 3 2 2 1 
 
  
298 096251g 25 39.1 5/5/2015 3 2 2 
 
1 2 
 
1 
  
  
299 726239f 28 40.3 5/5/2015 1 1 
  
1 2 2 1 1 
 
  
300 138279g 24 37.3 5/4/2015 2 1 
  
1 2 1 3 
  
2  
301 452598f 29 39 5/6/2015 3 2 
  
1 3 
 
1 
  
  
302 721233f 21 39 5/6/2015 3 2 
  
1 1 
 
1 
  
  
303 639310f 25 39.2 5/6/2015 3 2 
  
1 1 
 
1 
  
  
304 911008d 35 39.2 5/6/2015 3 2 
  
1 4 
 
1 
  
  
305 274340f 23 38.3 5/5/2015 3 2 
  
1 3 
 
1 
  
  
306 208011g 20 37.1 5/12/2015 3 1 
  
1 3 
 
1 
  
  
307 101611g 25 40.2 5/7/2015 2 1 1 
 
1 2 1 3 
  
1  
 127 
 
308 
              
  
309 899648d 28 40.5 5/13/2015 2 2 
  
1 2 2 2 4 
 
  
310 951881f 26 40.3 5/18/2015 2 2 
  
1 3 
 
3 
  
1  
311 869475c 30 37.5 5/6/2015 2 2 
  
1 3 
 
2 2 
 
  
312 
              
  
313 102660g 36 39.2 5/6/2015 1 1 1 gdm 1 2 2 2 3 
 
  
314 202105b 29 39.5 5/7/2015 1 1 2 
 
1 2 2 2 1 
 
  
315 132023g 25 40 5/6/2015 1 2 2 
 
1 3 2 2 1 
 
  
316 951822f 24 37.1 5/7/2015 2 2 
  
1 4 
 
3 
  
1  
317 678045f 26 37.1 5/8/2015 2 2 1 
 
1 4 
 
2 5 
spe with 
unfav cx   
318 138533g 
  
5/12/2015 2 1 
  
1 3 2 2 3 
 
  
319 049079g 21 
 
5/7/2015 1 2 
  
1 2 2 2 1 
 
  
320 512530f 19 38 5/7/2015 1 1 1 
 
1 4 1 2 1 
 
  
321 074792g 26 37 5/8/2015 3 2 
  
2 2 
 
1 
  
  
322 062299g 20 38 5/9/2015 1 1 
  
1 3 2 2 1 
 
  
323 173715g 27 39 5/9/2015 3 1 
  
1 3 
 
1 
  
  
324 130283g 28 40.4 5/9/2015 2 1 2 
 
1 3 3 2 4 
 
  
325 446951f 27 38.3 5/15/2015 2 1 
  
1 2 
 
3 
  
3  
326 183194g 29 37.2 5/11/2015 1 2 2 
 
1 3 2 2 1 
 
  
327 848752c 28 38.4 5/14/2015 1 2 2 
 
1 3 1 2 1 
 
  
328 126506g 28 39 5/11/2015 2 2 4 
 
1 4 1 3 
  
1  
329 669750f 35 39.2 5/14/2015 3 2 4 
 
1 3 
 
1 
  
  
330 951854f 38 37.3 5/14/2015 2 1 1 
 
1 4 
 
3 
  
3  
331 221580g 25 39.4 5/11/2015 3 2 4 
 
1 2 
 
1 
  
  
332 352893d 35 37.4 5/13/2015 3 2 2 
 
1 3 
 
1 
  
  
333 261735f 37 38.1 5/12/2015 3 1 
  
1 3 
 
3 
  
3  
334 833748d 35 37.4 5/11/2015 3 2 1 
 
1 4 
 
1 
  
  
335 065667g 26 40.6 5/12/2015 2 1 
  
1 4 2 2 3 
 
  
336 061550g 28 38.1 5/16/2015 2 1 2 
 
2 4 3 2 4 
 
  
337 769735f 27 40.2 5/15/2015 2 2 
  
1 2 3 2 4 
 
  
338 189808g 28 40.4 5/16/2015 2 1 
  
1 4 3 2 4 
 
  
339 686714f 29 40 5/15/2015 2 2 3 
 
1 4 3 2 4 
 
  
340 207180g 33 37.5 5/16/2015 2 1 2 
 
2 4 
 
2 2 
 
  
341 042132f 35 37.4 5/18/2015 2 2 
  
1 3 
 
3 
  
1  
342 092949g 35 37.3 5/19/2015 1 1 1 
 
1 4 1 2 1 
 
  
343 951889f 33 39 5/19/2015 1 2 
  
1 4 2 2 1 
 
  
344 076915g 26 40.4 5/19/2015 1 1 
  
1 2 2 2 1 
 
  
345 2 
             
  
346 291547d 32 38.4 5/18/2015 2 2 
  
1 2 
 
3 
  
1  
347 083063g 23 38.1 5/18/2015 3 2 
  
1 3 
 
1 
  
  
348 082648g 27 38.5 5/18/2015 2 1 
  
2 2 
 
1 
  
  
349 897200f 36 38 5/18/2015 3 2 
  
1 3 
 
1 
  
  
350 923212d 31 38.3 5/19/2015 2 2 
  
1 3 2 2 4 
 
  
351 163351g 33 40 5/19/2015 1 1 
  
1 4 2 2 1 
 
  
352 725705d 27 37.4 5/19/2015 3 2 
  
1 3 
 
3 
  
1  
353 190088g 21 38.1 5/25/2015 2 1 1 
 
1 3 3 2 4 
 
  
354 646196d 27 39.1 5/28/2015 2 2 
  
1 3 
 
3 
  
1  
355 084046g 21 40.4 5/21/2015 1 1 
  
1 3 2 2 1 
 
  
356 953913f 22 41.1 5/25/2015 2 1 1 
 
1 3 3 2 4 
 
  
357 146262g 35 39 5/25/2015 2 2 2 
Hypo 
thyroid 1 4 3 2 4 
 
  
358 072737g 23 40.5 5/19/2015 1 1 
  
1 3 3 2 1 
 
  
359 380092f 23 38.4 5/20/2015 2 2 2 
 
1 3 
 
3 
  
1  
360 702585f 22 37 5/20/2015 3 2 2 
 
1 3 
 
1 
  
  
361 082924d 33 38.4 5/20/2015 3 2 
  
2 3 
 
1 
  
  
362 217420g 24 39.3 5/20/2015 3 2 
  
1 3 
 
1 
  
  
363 181425d 27 39.2 5/20/2015 3 2 
  
1 3 
 
1 
  
  
364 131060g 19 39.1 5/20/2015 3 1 
  
1 2 
 
1 
  
  
365 145355g 33 39.1 5/20/2015 3 2 
  
1 2 
 
1 
  
  
366 
              
  
367 139798g 34 38.5 5/20/2015 3 2 2 
 
2 4 
 
1 
  
  
368 
              
  
369 203685g 27 38.5 5/21/2015 3 2 2 
 
1 4 
 
1 
  
  
370 328914f 24 38.6 6/3/2015 3 2 
  
1 3 
 
1 
  
  
371 797527f 30 37.1 5/20/2015 3 1 1 
 
1 3 
 
1 
  
  
372 071601g 22 38.6 5/20/2015 3 2 
  
1 3 
 
1 
  
  
373 187888g 25 38.2 5/20/2015 3 2 
  
2 2 
 
1 
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374 073067g 29 38.1 5/20/2015 3 2 2 
 
2 4 
 
1 
  
  
375 206263d 30 39.2 5/21/2015 3 2 
  
1 2 
 
1 
  
  
376 359325f 26 39.2 6/3/2015 3 2 
  
2 2 
 
1 
  
  
377 126329g 27 40.4 5/22/2015 2 1 
  
1 3 3 2 4 
 
  
378 892856f 40 38.4 5/22/2015 3 1 
  
2 3 
 
1 
  
  
379 116793g 26 39.2 5/22/2015 2 1 
  
1 3 3 2 4 
 
  
380 072638g 27 40.2 5/21/2015 2 2 
  
1 4 
 
3 
  
1  
381 128937g 26 39.4 5/22/2015 1 1 4 asthmatic 1 2 2 2 1 
 
  
382 366596c 33 37.6 5/21/2015 2 2 
  
2 3 2 3 
  
1  
383 888103f 24 39.3 5/23/2015 2 1 
  
1 3 3 2 4 
 
  
384 212720g 35 39 5/23/2015 1 1 
  
1 2 2 2 1 
 
  
385 953919f 21 41 5/24/2015 1 1 
  
2 2 3 2 1 
 
  
386 947461d 33 38.2 5/26/2015 3 1 
  
2 2 
 
3 
  
3  
387 100328g 29 40.5 5/23/2015 2 1 
  
1 
 
4 2 4 
 
  
388 953915f 29 40.5 5/25/2015 2 1 
  
1 3 3 2 3 
 
  
389 762236c 31 37.1 5/26/2015 2 2 1 
 
2 3 
 
3 
  
1  
390 953935f 16 37.3 5/26/2015 2 1 1 
 
1 3 
 
3 
  
2  
391 204554f 24 39.4 6/3/2015 3 2 
  
1 4 
 
1 
  
  
392 149242g 26 37.1 6/8/2015 3 1 
  
1 2 
 
1 
  
  
393 854919d 32 38.5 5/29/2015 2 2 2 
 
1 3 
 
3 
  
1  
394 001695c 29 39.2 6/9/2015 1 1 
  
1 2 1 2 1 
 
  
395 078333g 29 38.1 5/27/2015 3 1 
  
1 3 
 
1 
  
  
396 623110d 34 38 6/8/2015 3 2 1 
 
1 3 
 
1 
  
  
397 118419g 28 37.3 6/9/2015 1 1 2 
 
1 3 1 2 2 
 
  
398 
              
  
399 021064f 27 37.2 5/27/2015 3 2 
  
1 2 
 
1 
  
  
400 768486f 35 37 5/27/2015 3 1 2 
 
1 2 
 
1 
  
  
401 190524f 26 39.3 5/27/2015 3 2 3 
 
1 3 
 
1 
  
  
402 154252g 30 39.2 5/27/2015 3 2 4 asthmatic 1 3 
 
1 
  
  
403 323134d 28 37.1 5/27/2015 3 2 
  
1 3 
 
1 
  
  
404 844681d 25 41.1 5/27/2015 2 2 
  
1 2 
 
3 
  
1  
405 147043f 37 39 5/27/2015 3 2 
  
1 3 
 
1 
  
  
406 199140g 30 38.1 5/27/2015 3 1 2 
Gestational  
HT 1 4 
 
1 
  
  
407 194790g 24 37.5 6/17/2015 3 2 
  
2 3 
 
1 
  
  
408 802448d 27 39.3 5/30/2015 1 2 2 
 
1 3 2 2 1 
 
  
409 684530c 34 38.2 5/30/2015 1 2 2 
 
1 3 2 2 1 
 
  
410 096166g 31 38.1 5/31/2015 2 1 
  
1 3 
 
3 
  
2  
411 953983f 27 37.3 6/4/2015 2 2 1 
 
1 3 3 2 1 
 
  
412 506283f 22 39.1 5/29/2015 2 2 
  
1 2 
 
3 
  
2  
413 192109g 27 38.4 5/30/2015 2 1 
  
1 3 2 2 2 
 
  
414 953966f 28 40.4 6/1/2015 1 1 1 
 
1 2 1 2 1 
 
  
415 281954f 28 38.5 5/31/2015 2 2 
  
1 3 
 
3 
  
1  
416 627986d 32 38 5/30/2015 3 2 3 
 
1 3 
 
1 
  
  
417 956644f 26 40.1 6/7/2015 2 2 
  
1 3 3 2 3 
 
  
418 222367g 22 
 
6/3/2015 
          
  
419 470452f 33 39.1 6/5/2015 3 2 3 
 
1 2 
 
1 
  
  
420 202049g 28 39.5 6/6/2015 1 1 1 
 
1 2 2 2 1 
 
  
421 130752g 30 38.2 6/2/2015 2 2 
  
1 3 2 2 1 
 
  
422 261744f 23 40.1 6/2/2015 3 2 
  
1 3 
 
1 
  
  
423 090017g 23 40 6/6/2015 1 1 
  
1 3 1 2 1 
 
  
424 livery 22 
 
6/2/2015 
          
  
425 057008f 31 40.4 6/4/2015 2 2 
  
1 3 2 2 4 
 
  
426 633638c 26 39.3 6/3/2015 3 1 
  
1 3 
 
1 
  
  
427 262996f 39 38.1 6/3/2015 3 2 2 
 
1 2 
 
1 
  
  
428 007692f 27 37 6/3/2015 3 2 
  
1 2 
 
1 
  
  
429 192139g 35 37 6/3/2015 3 2 3 
Asthma, 
GDM 2 4 
 
1 
  
  
430 413499f 26 39 6/3/2015 3 2 
  
1 2 
 
1 
  
  
431 505554f 29 39.5 6/3/2015 3 2 
  
2 3 
 
1 
  
  
432 216330g 34 38.1 6/3/2015 3 2 
  
1 4 
 
1 
  
  
433 220435g 27 40.4 6/4/2015 1 2 
  
1 2 1 2 1 
 
  
434 098742g 28 38.5 6/3/2015 3 1 
  
1 2 
 
1 
  
  
435 455217f 32 40 6/3/2015 2 2 
  
1 3 
 
3 
  
1  
436 211682g 23 38.6 6/3/2015 1 1 
  
1 1 3 2 1 
 
  
437 349671d 31 39.3 6/3/2015 3 2 
  
1 3 
 
1 
  
  
438 121325g 34 38.1 6/3/2015 1 1 
  
1 2 3 2 1 
 
  
439 192641c 25 37.5 6/3/2015 3 2 3 
 
1 2 
 
1 
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440 458320f 24 39.6 6/3/2015 3 2 
  
1 2 
 
1 
  
  
441 111527g 29 38.1 6/3/2015 3 2 
  
1 2 
 
1 
  
  
442 817863a 26 39.2 6/8/2015 3 2 2 
 
1 3 
 
1 
  
  
443 075147g 25 40.3 6/9/2015 1 1 
  
1 2 
 
2 1 
 
  
444 217833f 30 37.5 6/9/2015 3 2 
  
1 3 
 
1 
  
  
445 402567f 26 38.5 6/10/2015 3 2 
  
1 3 
 
1 
  
  
446 104114g 39 38.3 6/10/2015 3 2 2 
 
1 2 
 
1 
  
  
447 216894d 36 38.5 6/10/2015 3 2 2 
 
1 2 
 
1 
  
  
448 886816f 26 38.3 6/10/2015 3 2 
  
1 2 
 
1 
  
  
449 116578f 30 38.3 6/10/2015 3 2 
  
1 3 
 
1 
  
  
450 099070g 23 38.2 6/10/2015 3 1 
  
1 3 
 
1 
  
  
451 
              
  
452 
              
  
453 092851g 27 38.2 6/10/2015 3 1 4 Asthma 2 4 
 
1 
  
  
454 123667g 40 37.4 6/10/2015 2 1 
  
1 3 
 
3 
  
3  
455 122864g 35 38 6/10/2015 3 2 
  
2 3 
 
1 
  
  
456 841009d 24 37.1 6/10/2015 3 2 
  
2 3 
 
1 
  
  
457 043076f 29 37.2 6/10/2015 3 2 2 
 
1 3 
 
1 
  
  
458 
 
30 
            
  
459 140163g 25 40.3 6/11/2015 3 2 
  
1 4 
 
1 
  
  
460 216466g 29 39.5 6/11/2015 3 2 
  
1 3 
 
1 
  
  
461 739432d 33 38 6/17/2015 3 2 1 
 
1 3 
 
1 
  
  
462 844221f 31 37 6/11/2015 1 1 
  
2 3 3 2 1 
 
  
463 084394g 24 40 6/11/2015 2 1 2 
 
2 2 3 2 3 
 
  
464 274120f 25 38.3 6/17/2015 3 2 2 
 
2 3 
 
1 
  
  
465 224514g 22 40.4 6/11/2015 1 1 
  
1 3 
 
2 1 
 
  
466 175986g 27 40.3 6/12/2015 2 1 2 
 
1 3 3 2 3 
 
  
467 186846g 26 38.1 6/12/2015 3 2 
  
2 3 
 
1 
  
  
468 244541g 19 39.1 6/13/2015 1 1 
  
1 1 2 2 1 
 
  
469 676746f 23 39.1 6/12/2015 2 2 2 
 
1 4 3 2 3 
 
  
470 209724g 23 37.4 6/12/2015 3 1 
  
1 3 
 
1 
  
  
471 485196f 23 38 6/13/2015 3 2 
  
1 2 
 
1 
  
  
472 330784f 25 37 6/19/2015 3 2 
  
1 4 
 
1 
  
  
473 956629f 24 38.6 6/13/2015 2 1 1 
  
1 2 2 4 
 
  
474 229974g 27 40.3 6/13/2015 2 2 
  
2 3 3 2 4 
 
  
475 068533f 23 37.6 6/13/2015 3 2 
  
1 4 
 
1 
  
  
476 903742f 29 38.1 6/15/2015 3 2 3 
 
1 4 
 
1 
  
  
477 712537f 25 38.5 6/16/2015 3 2 
  
1 2 
 
1 
  
  
478 176877g 28 38.6 6/16/2015 3 2 
  
1 3 
 
1 
  
  
479 223696g 21 39.1 6/16/2015 1 1 2 
 
2 3 3 2 1 
 
  
480 211093g 36 40 6/16/2015 2 2 2 
 
1 2 3 2 4 
 
  
481 245475g 27 39.3 6/16/2015 1 1 1 
 
1 4 2 2 1 
 
  
482 079693d 36 37 6/15/2015 3 2 
  
1 4 
 
1 
  
  
483 191827g 22 40.5 6/16/2015 1 1 
  
1 4 3 2 1 
 
  
484 110009g 23 38 6/16/2015 3 2 
  
1 3 
 
1 
  
  
485 122786g 27 40.2 6/15/2015 1 1 
  
1 2 3 2 1 
 
  
486 194245g 29 37.1 6/17/2015 3 2 1 
 
1 3 
 
1 
  
  
487 348884f 23 39.4 6/17/2015 3 2 
  
1 2 
 
1 
  
  
488 284547f 24 38.4 6/17/2015 3 2 
  
1 4 
 
1 
  
  
489 229447g 31 39.2 6/17/2015 3 2 
  
1 4 
 
1 
  
  
490 956644f 26 40.1 6/17/2015 2 2 
  
1 2 3 2 3 
 
  
491 211280d 29 37.6 6/18/2015 3 2 2 
 
1 4 
 
1 
  
  
492 916771c 29 39.4 6/18/2015 3 2 
  
1 2 
 
1 
  
  
493 242011g 31 40.6 6/18/2015 2 1 
  
1 3 3 2 3 
 
  
494 182292g 23 37.1 6/17/2015 3 1 2 
 
2 3 
 
1 
  
  
495 214801g 25 40.4 6/28/2015 1 1 2 
 
1 4 3 2 1 
 
  
496 806812d 30 38 6/17/2015 3 2 2 
 
1 3 
 
1 
  
  
497 166281g 33 37.5 6/17/2015 2 1 3 
 
1 3 
 
3 
  
2  
498 869182d 27 37.6 6/18/2015 3 2 
  
1 2 
 
1 
  
  
499 817120d 25 39.1 6/18/2015 3 2 
  
2 4 
 
1 
  
  
500 703722f 28 39.1 6/18/2015 3 2 
  
1 2 
 
1 
  
  
501 234103f 31 39.1 6/18/2015 3 2 
  
1 3 
 
1 
  
  
502 
 
21 
            
  
503 630535d 28 38 6/20/2015 3 2 3 
 
1 3 
 
1 
  
  
504 108187f 24 38.1 6/20/2015 3 2 
  
1 2 
 
1 
  
  
505 989536d 31 38.2 6/26/2015 2 2 
  
1 3 
 
3 
  
1  
506 467714d 26 37.5 6/27/2015 3 2 
  
1 2 
 
1 
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507 040028g 29 37.3 6/27/2015 3 2 1 GDM 1 3 
 
1 
  
  
508 
 
22 
            
  
509 496885f 30 39.4 6/20/2015 1 2 
  
2 4 2 2 1 
 
  
510 089494g 37 40.1 6/20/2015 1 2 
  
2 3 1 2 1 
 
  
511 956681f 24 38.4 6/20/2015 3 2 
  
2 2 
 
1 
  
  
512 094519g 20 38.3 6/22/2015 3 2 
  
1 3 
 
1 
  
  
513 607108d 27 40.5 6/23/2016 1 2 
  
1 4 2 2 1 
 
  
514 170731g 23 37.3 6/23/2015 3 1 
  
2 2 
 
1 
  
  
515 
 
22 
            
  
516 449237c 30 38.1 6/23/2015 3 2 
  
1 3 
 
1 
  
  
517 155335g 24 38.1 6/24/2015 3 2 
  
1 2 
 
1 
  
  
518 948860f 26 39.6 6/24/2015 3 2 
  
1 2 
 
1 
  
  
519 018411f 29 38 6/24/2015 3 2 
  
1 2 
 
1 
  
  
520 406802f 26 38.4 6/24/2015 3 2 
  
1 2 
 
1 
  
  
521 328791f 25 39.5 6/24/2015 3 2 
  
1 3 
 
1 
  
  
522 896315d 26 37.6 6/24/2015 3 2 
  
1 3 
 
1 
  
  
523 272317b 38 37 6/24/2015 3 2 
  
1 2 
 
1 
  
  
524 116193g 34 39.1 6/24/2015 3 2 
  
1 2 
 
1 
  
  
525 144271g 36 39.5 6/24/2015 2 1 2 
 
1 2 3 2 4 
 
  
526 250949g 31 38.1 6/24/2015 2 2 
  
2 3 2 2 4 
 
  
527 928793f 33 39.3 6/24/2015 2 1 2 
 
1 3 3 2 3 
 
  
528 497941f 28 40.1 7/9/2015 3 2 
  
2 3 
 
1 
  
  
529 838422f 30 38.1 6/24/2015 3 1 
  
2 2 
 
1 
  
  
530 945127d 30 37.6 6/24/2015 1 2 2 
 
1 4 3 2 1 
 
  
531 399679f 26 38.3 6/24/2015 3 2 
  
1 3 
 
3 
  
1  
532 689211c 27 40.1 6/26/2015 2 2 
  
2 4 2 2 4 
 
  
533 150850g 30 39.2 6/26/2015 3 2 2 
 
1 3 
 
1 
  
  
534 308156f 25 37 6/26/2015 3 2 
  
1 4 
 
1 
  
  
535 786170d 31 38.5 6/26/2015 2 2 
  
2 2 
 
3 
  
2  
536 230535c 33 39.6 6/26/2015 3 2 
  
1 3 
 
1 
  
  
537 500861f 28 39 6/27/2015 2 1 2 
 
1 4 
 
2 4 
 
  
538 130524g 19 38.1 7/9/2015 1 1 
  
1 2 2 2 4 
 
  
539 210473g 27 40 6/28/2015 1 1 
  
1 3 2 2 1 
 
  
540 237189g 25 38.5 7/9/2015 1 1 
  
2 2 3 2 1 
 
  
541 909671f 19 38.2 6/28/2015 1 1 
  
2 2 2 2 1 
 
  
542 025993d 31 38.3 6/30/2015 3 2 2 
 
1 4 
 
1 
  
  
543 134606g 29 40.3 6/29/2015 2 1 
  
1 2 3 2 4 
 
  
544 282957f 37 37.1 6/29/2015 3 2 2 
 
1 3 
 
1 
  
  
545 22 
             
  
546 254935g 24 40.2 7/9/2015 1 1 
  
1 3 3 2 1 
 
  
547 853919d 25 38.6 7/1/2015 3 2 
  
1 2 
 
1 
  
  
548 872981d 26 38 7/1/2015 3 2 
  
2 2 
 
1 
  
  
549 710576d 29 39 7/1/2015 3 2 
  
1 4 
 
1 
  
  
550 379075f 25 38.4 7/1/2015 3 2 
  
1 3 
 
1 
  
  
551 606909d 32 38 7/1/2015 3 2 
  
1 2 
 
1 
  
  
552 097094f 36 39.4 7/1/2015 3 2 2 
Hyrpo 
thyroid 1 3 
 
1 
  
  
553 217556f 25 38.3 7/1/2015 3 2 
  
1 2 
 
1 
  
  
554 130374f 26 40.2 7/30/2015 3 2 
  
1 3 2 2 4 
 
  
555 556225d 33 38.2 7/1/2015 3 2 2 
 
1 3 
 
1 
  
  
556 059657f 30 38.1 7/1/2015 3 2 
  
1 3 
 
1 
  
  
557 943536f 19 38.2 7/5/2015 1 1 
  
1 2 2 2 1 
 
  
558 243946g 21 40 7/5/2015 1 2 
  
1 3 3 2 1 
 
  
559 408695d 28 38.3 7/6/2015 3 2 
  
1 2 
 
1 
  
  
560 118217g 25 37.6 7/4/2015 2 1 
  
1 2 1 2 2 
 
  
561 156859f 33 37 7/5/2015 3 2 2 
 
2 3 
 
1 
  
  
562 719631d 24 38.1 7/4/2015 1 2 
  
1 3 4 2 1 
 
  
563 007124d 33 39.2 7/4/2015 2 2 2 
 
1 2 
 
2 4 
 
  
564 960347f 20 41 7/4/2015 1 1 
  
1 2 1 2 4 
 
  
565 222867g 26 38.1 7/3/2015 2 1 
  
1 3 3 2 3 
 
  
566 225470g 24 38.4 7/2/2015 2 1 1 
 
1 2 
 
2 2 
 
  
567 129134g 27 39.6 7/4/2015 2 1 2 
 
1 4 3 2 4 
 
  
568 960332f 25 39.6 7/3/2015 2 2 
  
1 3 3 2 3 
 
  
569 983088d 30 37.3 7/3/2015 3 2 
  
1 2 
 
1 
  
  
570 0 
             
  
571 220257g 30 40.1 7/2/2015 1 1 
  
1 3 2 2 1 
 
  
572 960315f 23 40.6 7/2/2015 2 1 
  
1 3 
 
2 4 
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573 193778g 31 37.2 7/5/2015 3 1 
  
1 2 
 
1 
  
  
574 0 
             
  
575 
              
  
576 730853d 25 37.6 7/7/2015 1 2 
  
2 3 2 2 1 
 
  
577 0 
             
  
578 213823g 25 39.3 7/12/2015 2 1 
  
1 3 3 2 3 
 
  
579 142825g 23 37.6 7/7/2015 1 1 3 
 
1 4 2 2 1 
 
  
580 706600f 35 38.2 7/7/2015 3 2 2 
 
1 4 
 
1 
  
  
581 0 
             
  
582 
 
0 
            
  
583 182360g 21 39.5 7/7/2015 1 1 
  
2 2 2 2 1 
 
  
584 192296g 22 40.5 7/8/2015 1 1 
  
2 2 3 2 1 
 
  
585 380462f 25 38.6 7/8/2015 3 2 
  
1 3 
 
1 
  
  
586 799474f 24 38.5 7/8/2015 3 2 
  
1 3 
 
1 
  
  
587 252604g 22 38.5 7/8/2015 3 2 
  
2 3 
 
1 
  
  
588 002470d 35 38.3 8/8/2015 3 2 
  
1 3 
 
1 
  
  
589 234870g 30 40.2 7/9/2014 1 1 
  
1 3 2 2 1 
 
  
590 146755g 24 38.3 7/8/2015 3 1 
  
1 2 
 
1 
  
  
591 392402f 29 40 7/8/2015 2 2 
  
1 3 
 
2 4 
 
  
592 127765g 28 37.2 7/8/2015 3 2 
  
1 4 
 
1 
  
  
593 200303g 26 39.4 7/8/2015 1 1 
  
1 3 2 2 1 
 
  
594 935196a 24 38.5 7/15/2015 1 1 
  
1 2 1 2 2 
 
  
595 325882f 26 38.6 7/10/2015 3 2 
  
1 3 
 
1 
  
  
596 151897g 24 39.2 7/14/2015 2 1 1 
 
1 3 3 2 3 
 
  
597 208412g 30 40.1 7/9/2015 1 2 
  
1 3 2 2 1 
 
  
598 118131g 25 38.6 7/10/2015 1 1 1 
 
1 3 1 2 1 
 
  
599 180095g 28 38.5 7/15/2015 3 2 
  
1 3 
 
1 
  
  
600 170479g 38 37.2 7/10/2015 2 2 2 
 
1 3 3 2 4 
 
  
601 141154b 33 37.2 7/11/2015 3 2 2 
 
1 3 
 
1 
  
  
602 203839g 25 40.5 7/11/2015 1 2 
  
1 2 2 2 1 
 
  
603 960385f 27 40 7/11/2015 1 1 
  
1 3 2 2 1 
 
  
604 238848g 27 37.3 7/11/2015 1 2 
  
2 3 
 
3 
  
1  
605 261052g 29 37.2 7/15/2015 3 2 
  
1 3 
 
3 
  
1  
606 
 
22 
            
  
607 142840g 21 39 7/12/2015 1 1 
  
1 3 1 2 1 
 
  
608 326250f 21 37.3 7/13/2015 3 2 
  
1 3 
 
1 
  
  
609 416998d 28 37.1 7/11/2015 2 1 2 
Hypo 
thyroid 1 4 
 
3 
  
3  
610 114473g 22 
 
7/14/2015 
          
  
611 171730g 35 39 7/13/2015 1 2 2 
 
1 4 2 2 1 
 
  
612 180107f 28 40.3 7/13/2015 1 1 
  
1 3 2 2 1 
 
  
613 130980g 24 40.4 7/14/2015 1 1 
  
1 2 2 2 1 
 
  
614 147380g 29 39.2 7/13/2015 1 1 
  
1 2 1 2 1 
 
  
615 763989f 40 37.3 7/13/2015 1 2 2 
 
1 3 1 2 1 
 
  
616 163320g 25 40.2 7/14/2015 1 1 2 
 
1 3 2 2 1 
 
  
617 202423g 34 39 7/13/2015 1 1 1 
 
1 2 2 2 1 
 
  
618 600721d 35 38 7/15/2015 3 2 
  
1 2 
 
1 
  
  
619 268979g 29 41.5 7/14/2015 1 1 
  
1 3 1 2 1 
 
  
620 102054f 31 38.4 7/15/2015 3 2 
  
2 3 
 
1 
  
  
621 372107d 29 37.4 7/15/2015 1 2 1 
 
2 3 1 2 4 
 
  
622 857609d 26 38.6 7/15/2015 3 2 
  
1 3 
 
1 
  
  
623 149075g 22 40.5 7/16/2015 1 1 
  
1 3 1 2 1 
 
  
624 
 
22 
            
  
625 133955g 28 38.3 7/15/2015 1 1 
  
1 2 2 2 1 
 
  
626 025418g 24 39 7/16/2015 1 1 
  
1 2 1 2 1 
 
  
627 967243f 28 38.3 7/21/2015 1 1 1 
 
2 3 2 2 1 
 
  
628 245023g 20 38.3 7/16/2015 2 1 
  
1 2 4 3 
  
2  
629 964519f 27 41.1 7/17/2015 1 1 
  
2 2 2 2 1 
 
  
630 979211d 34 38.1 7/16/2015 1 2 2 
 
2 3 2 2 1 
 
  
631 176603g 21 39.3 7/16/2015 2 1 
  
1 3 2 2 3 
 
  
632 149826g 24 39 7/16/2015 2 1 
  
1 2 
 
2 2 
 
  
633 130218g 26 39 7/21/2015 1 1 1 
 
1 2 2 2 1 
 
  
634 964526f 26 39.2 7/17/2015 1 1 
  
1 3 
 
2 2 
 
  
635 531524d 31 39.4 7/21/2015 1 2 1 
 
2 4 2 2 1 
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electcs dos 
bld 
loss 
Intra 
op 
Bld 
trans 
Hosp 
stay 
Evi 
endo 
Feb 
morbi sursite 
Ther 
anti 
Indi 
ther theraothe allergic 
R0 
eadmis 
Anti 
bio1 
Hos 
visit 
Rea 
read 
Read 
oth 
Hosp 
stay1 
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 3 2 2 2 2 
  
2 2 
     1 1 1 
 
2 4 2 2 2 2 
  
2 2 
     1 2 2 1 2 3 2 2 1 2 
  
2 2 
     1 1 1 
 
2 5 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 3 2 2 1 2 
  
2 1 2 2 4 
 
1 
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 4 2 2 2 2 
  
2 2 2 2 
  
2 
                   
 
1 1 
 
2 7 1 
 
2 1 2 
 
2 2 2 1 
   
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     
                   
 
1 1 
 
2 3 2 2 2 2 
  
2 2 2 1 
   
 
1 1 
 
2 5 2 2 1 1 3 
 
2 2 
     
 
1 2 1 1 5 2 2 2 2 
  
2 2 
     
 
1 2 
  
5 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 3 2 2 2 2 
  
2 2 
     2 1 2 
 
2 6 2 2 2 2 
  
2 2 
     
 
1 2 
 
2 14 1 
 
1 1 2 
 
2 2 
     
 
1 2 3 2 6 2 
 
2 1 4 
 
2 2 
     1 1 2 
 
2 5 2 2 2 2 
  
2 2 
     
 
2 3 3 1 5 2 2 2 1 4 
 
2 2 
     
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 4 2 2 1 2 
  
2 2 
     
 
1 
 
2 2 5 2 2 2 2 
  
2 2 
     1 1 1 
 
2 4 2 2 2 2 
  
2 2 
     1 1 1 
 
2 5 2 2 2 2 
  
2 2 
     1 1 1 
 
2 7 2 2 2 2 
  
2 2 
     1 1 2 
 
2 4 2 2 2 2 
  
2 2 
     1 1 1 
 
2 5 2 2 2 2 
  
2 2 
     1 1 1 
 
2 4 2 2 2 2 
  
2 2 
     1 1 1 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 2 3 2 6 2 2 2 1 1 
 
2 2 
     
  
1 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 2 
 
2 5 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 2 
 
2 5 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 5 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 5 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 1 3 2 5 2 2 2 2 
  
2 1 1 2 1 
 
3 
1 1 1 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 2 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 2 
 
2 4 2 2 2 2 
  
2 2 
  
2 
  
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     5 1 2 
 
2 4 2 2 2 2 
  
2 2 
     1 1 1 
 
2 5 2 2 2 2 
  
2 2 
     
 
1 2 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 2 
 
2 7 2 2 2 2 
  
2 2 
     
 
1 2 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 5 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     1 1 1 
 
2 4 2 2 2 2 
  
2 2 
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1 1 
 
2 7 2 2 2 2 
  
2 2 
     5 1 2 1 2 5 2 2 2 2 
  
2 2 
     1 1 1 
 
2 5 2 2 2 2 
  
2 2 
     1 1 1 
 
2 3 2 2 2 2 
  
2 2 
     2 1 1 
 
2 4 2 2 2 2 
  
2 2 
     3 1 2 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 5 1 2 2 1 2 
 
2 2 
     
 
1 2 
 
2 5 1 2 2 1 2 
 
1 2 
     
 
1 1 
 
2 4 2 2 2 2 2 
 
2 2 
     1 1 1 
 
2 6 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 4 2 2 1 2 3 
 
2 2 
     
 
1 2 
 
2 5 2 2 2 2 
  
2 2 
     
 
1 2 1 1 5 1 
  
1 2 
 
2 2 
     1 1 1 
 
2 4 2 2 2 2 
  
2 2 
     1 1 1 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 2 1 2 4 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 1 
  
7 2 2 2 2 
  
2 2 
     1 1 1 
  
4 2 2 2 2 
  
2 2 
     5 1 1 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 2 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 5 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 2 1 1 5 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 5 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 2 1 2 4 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 3 2 2 2 2 
  
2 2 
     1 1 2 
 
1 13 2 2 2 1 4 
 
2 2 
     
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     
 
3 1 
 
2 4 2 2 2 2 
  
2 2 
     5 1 1 
 
2 4 2 2 2 2 
  
2 2 
     1 1 2 
 
2 6 2 2 2 2 
  
2 2 
     1 
 
1 
 
2 4 2 2 2 2 
  
2 2 
     2 1 1 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 8 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 2 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 8 1 2 2 1 2 
 
2 2 
     
 
1 1 
 
2 5 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 5 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     1 1 1 
 
2 4 2 2 2 2 
  
2 2 
     1 1 2 
 
2 5 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 6 2 2 2 2 
  
2 2 
     
 
2 3 1 1 4 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 3 2 2 1 1 
  
2 2 
     
 
1 1 
 
2 5 2 2 2 2 
  
2 2 
     
                   
 
1 2 3 2 3 2 2 2 2 
  
2 2 
     
                   
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     1 1 1 
 
2 3 2 2 2 2 
  
2 2 
     3 1 2 
 
2 5 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 4 2 2 1 2 
  
2 2 
     2 1 2 
 
2 4 2 2 2 2 
  
2 2 
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2 1 2 
 
2 4 2 2 2 2 
  
2 2 
     1 1 1 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 2 
 
2 3 2 2 2 2 
  
2 2 
     
                   
 
1 1 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 5 2 2 2 2 
  
2 2 
     
 
1 2 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 8 1 
  
1 2 
 
2 2 
     
 
2 2 
 
2 5 2 2 2 1 4 
 
2 2 
     1 1 2 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     1 1 1 
 
2 10 1 
  
1 1 
 
2 
 
2 
    
 
1 1 
 
2 3 2 2 1 2 
  
2 2 
     
 
1 2 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 2 3 2 5 2 2 2 2 
  
2 2 
     1 1 1 
 
2 7 2 2 2 2 
  
2 1 2 
 
3 
 
3 
                   
 
1 1 
 
2 4 2 2 1 2 
  
2 2 
     1 1 1 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 2 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     
                   
    
2 5 2 2 2 2 
  
2 2 
     6 1 1 
 
2 4 2 2 1 1 
  
2 2 
     
 
1 2 
 
2 6 2 2 2 2 
  
2 2 
     4 1 1 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 5 2 2 2 2 
  
2 2 
     
 
1 2 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     5 1 1 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     5 1 1 
 
2 4 2 2 2 2 
  
2 2 
     2 1 2 
 
2 3 2 2 2 2 
  
2 2 
     
 
2 1 
 
2 4 2 2 2 2 
  
2 2 
     1 1 2 
  
4 2 
 
2 2 
  
2 2 
     
1 2 2 3 2 4 2 2 2 1 4 
adhesion, 
longsx 2 2 
     6 1 2 
 
2 6 2 2 2 2 
  
2 2 
     1 1 2 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 2 
 
2 3 2 2 2 2 
  
2 2 
     1 1 1 
 
2 3 2 2 1 2 
  
2 2 
     
                   1 1 1 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 5 2 2 2 2 
  
2 2 
     1 1 1 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 3 2 2 2 2 
  
2 2 
     1 1 1 
 
2 5 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 3 2 2 2 2 
  
2 2 
     
                   
 
1 2 
 
2 7 1 
  
1 2 
 
2 2 
     
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 2 
 
2 10 
 
1 
 
1 1 
 
2 2 
     
 
1 1 
 
2 3 2 2 2 2 
  
2 2 
     1 1 1 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 4 2 2 1 2 
  
2 2 
     
 
1 1 
 
2 3 2 2 2 2 
  
2 2 
     1 1 1 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 2 
 
2 4 2 2 2 2 
  
2 2 
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1 1 1 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 5 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 5 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 2 
 
2 3 2 2 1 2 
  
2 2 
     1 1 2 
 
2 7 2 2 2 2 
  
2 2 
     1 1 1 
 
2 14 2 2 2 
   
2 2 
     
 
1 1 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 1 
  
4 2 2 2 2 
  
2 2 
     
                   2 1 1 
 
2 5 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 2 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 5 2 2 2 2 
  
2 2 
     1 2 2 
 
2 3 2 2 2 2 
  
2 2 
     3 1 2 
 
2 3 2 2 2 2 
  
2 2 
     1 1 1 
 
2 3 2 2 2 2 
  
2 2 
     
 
2 3 1 1 3 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 3 2 2 2 2 
  
2 2 
     1 1 1 
 
2 9 2 2 2 2 
  
2 2 
     1 1 1 
 
2 3 2 2 2 2 
  
2 2 
     1 1 1 
 
2 3 2 2 2 2 
  
2 2 
     6 1 1 
 
2 3 2 2 2 2 
  
2 2 
     1 1 1 
 
2 3 2 2 2 2 
  
2 2 
     2 1 1 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 3 2 2 2 1 4 
post-op  
atonic PPH 2 2 
     
 
1 1 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 7 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 5 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 6 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 2 
 
1 6 2 2 2 2 
  
2 2 
     1 1 1 
 
2 6 2 2 2 2 
  
2 2 
     6 1 1 
 
2 3 2 2 2 2 
  
2 2 
     1 1 1 
 
2 4 2 2 1 1 1 
 
2 2 
     1 1 1 
 
2 6 2 2 2 2 
  
2 2 
     6 1 1 
 
2 4 2 2 2 2 2 
        
 
1 1 
 
2 4 
             2 1 1 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 3 2 2 2 2 
  
2 2 
     1 1 2 
 
1 3 2 2 2 2 
  
2 2 
     1 1 1 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 2 
 
2 5 2 2 2 2 
  
2 2 
     
 
1 2 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 5 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 5 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 6 2 2 1 2 
  
2 2 
     4 1 1 
 
2 4 2 2 1 2 
  
2 2 
     
 
1 1 
 
2 5 2 2 2 2 
  
2 2 
     4 1 1 
 
2 5 2 2 2 2 
  
2 2 
     
                   1 1 1 3 2 4 2 2 1 1 1 
 
2 1 1 2 1 
 
2 
1 1 1 
 
2 5 2 2 2 2 
  
2 2 
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1 1 1 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 3 2 2 2 2 
  
2 2 
     1 1 1 
 
2 3 2 2 2 2 
  
2 2 
     1 1 1 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 3 2 2 2 2 
  
2 2 
     
                   1 1 2 
 
2 7 1 
 
2 1 2 sepsis 1 2 
     1 1 1 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 3 2 2 2 2 
  
2 2 
     1 1 1 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 5 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 3 2 2 2 2 
  
2 2 
     1 1 1 
 
2 4 2 2 2 2 
  
2 2 
     1 1 1 
 
2 3 2 2 2 2 
  
2 2 
     1 1 1 
 
2 3 2 2 2 2 
  
2 2 
     1 1 1 
 
2 3 2 2 2 2 
  
2 2 
     2 1 1 
 
2 4 2 2 1 2 
  
2 2 
     
 
1 2 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 3 2 2 2 2 
  
2 2 
     1 1 1 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     
                   
 
1 1 
 
2 6 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     2 1 1 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 4 2 2 2 2 
  
2 1 1 3 5 
breast 
abscess 
 
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     1 1 1 
 
2 3 2 2 2 2 
  
2 2 
     6 1 1 
 
2 3 2 2 2 2 
  
2 2 
     1 1 1 
 
2 6 1 
  
1 2 
 
2 2 
     7 1 1 
 
2 3 2 2 2 2 
  
2 2 
     1 1 1 
 
2 3 2 2 2 2 
  
2 2 
     2 1 1 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     
                   
 
1 1 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 3 2 2 2 2 
  
2 2 
     
                   
 
1 2 1 2 3 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 3 2 2 2 2 
  
2 2 
     
 
2 1 
 
2 5 2 2 2 2 
  
2 2 
     
 
2 1 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 5 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 8 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 3 2 2 1 1 3 
 
2 1 1 2 1 
 
2 
 
1 1 
 
2 7 2 2 2 2 
  
2 2 
     5 1 1 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 3 2 2 2 2 
  
2 2 
     2 1 1 3 2 3 2 2 2 2 
  
2 2 
     
 
1 2 
 
2 6 2 1 2 2 
  
2 2 
     
  
1 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 8 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 2 
 
2 4 1 2 2 2 
  
2 2 
     1 1 1 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     6 1 1 
 
2 5 2 2 2 2 
  
2 2 
     1 1 1 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 3 2 2 2 2 
  
2 2 
     1 1 1 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
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1 1 
 
2 6 2 2 2 2 
  
2 2 
     
 
1 2 
 
2 4 2 2 2 1 4 
intra op  
foul 
smelling  
liqour 2 2 
     
 
1 2 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 6 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 3 2 2 2 2 
  
2 2 
 
2 
   
 
1 1 
 
2 6 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 6 2 2 2 2 
  
2 2 
     
 
1 2 
 
2 4 2 2 2 2 
  
2 2 
     
                   
 
1 1 
 
2 3 2 2 2 2 
  
2 2 
     5 1 1 
 
2 4 2 2 2 2 
  
2 2 
     2 1 1 
 
2 4 2 2 2 2 
  
2 2 
     1 1 1 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 2 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 2 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 7 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 3 2 2 2 2 
  
2 2 
     1 1 1 
 
2 3 2 2 2 2 
  
2 2 
     5 1 1 
 
2 4 2 2 2 2 
  
2 2 
     6 1 1 
 
2 3 2 2 2 2 
  
2 2 
     2 1 1 
 
2 4 2 2 2 2 
  
2 2 
     2 1 1 
 
2 4 2 2 2 2 
  
2 2 
     5 1 1 
 
2 4 2 2 2 2 
  
2 2 
     
                   1 1 1 
 
2 3 2 2 2 2 
  
2 2 
     
                   1 1 1 
 
2 3 2 2 2 2 
  
2 2 
     1 1 1 
 
2 4 2 2 2 2 
  
2 2 
     2 1 1 
 
2 3 2 2 2 2 
  
2 2 
     6 1 1 
 
2 4 2 2 2 2 
  
2 2 
     5 1 2 
 
2 4 1 2 2 1 2 
 
2 2 
     1 1 1 
 
2 3 2 2 2 2 
  
2 2 
     1 1 1 
 
2 5 2 2 2 2 
  
2 2 
     7 1 1 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 3 2 2 2 2 
  
2 2 
     2 1 2 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 5 2 2 2 2 
  
2 2 
     
 
2 2 
 
2 6 2 2 2 2 
  
2 2 
     
 
2 3 1 1 5 2 2 2 1 4 
increased  
blood loss 2 2 
     
 
1 1 
 
2 7 2 2 2 2 
  
2 2 
     
 
2 3 1 1 6 2 2 2 1 4 PPH 2 2 
     
 
1 1 
 
2 5 2 
 
2 1 2 
 
2 2 
     
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     
 
2 3 1 1 8 2 2 2 1 4 Peritonotis 2 2 
     
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 5 2 2 2 2 
  
2 2 
     1 1 1 
 
2 3 2 2 2 2 
  
2 2 
     2 1 1 
 
2 14 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 5 2 2 2 2 
  
2 2 
     2 1 1 
 
2 4 2 2 2 2 
  
2 2 
     5 1 1 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     
                   1 1 1 
 
2 4 2 2 2 2 
  
2 2 
     3 1 2 
 
2 4 2 2 2 2 
  
2 2 
     1 1 1 
 
2 4 2 2 2 2 
  
2 2 
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1 1 1 
 
2 3 2 2 2 2 
  
2 2 
     5 1 1 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     1 1 1 
 
2 4 2 2 2 2 
  
2 2 
     2 1 1 
 
2 4 2 2 2 2 
  
2 2 
     1 1 2 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 6 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 5 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 5 2 2 2 2 
  
2 2 
     
 
1 2 
 
2 6 2 2 2 2 2 
 
2 2 
     
 
1 1 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 2 
 
2 5 2 2 2 2 
  
2 2 
     1 1 1 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     
                   6 1 1 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 2 1 1 5 2 2 2 2 
  
2 2 
     
 
1 2 
 
2 4 2 2 2 1 
  
2 2 
     1 1 1 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     
                   
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     
2 1 1 
 
2 10 2 2 2 2 
 
Long HS 
for baby 
sake 2 2 
     1 1 1 
 
2 5 2 2 2 2 
  
2 2 
     7 1 1 
 
2 3 2 2 2 2 
  
2 2 
     5 2 2 
 
2 4 2 2 2 2 
  
2 2 
     1 1 1 
 
2 5 2 2 2 2 
  
2 2 
     1 1 1 
 
2 4 2 2 2 2 
  
2 2 
     1 1 1 
 
2 5 2 2 2 2 
  
2 2 
     
 
1 2 
 
2 4 2 2 2 2 
  
2 2 
     2 1 1 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 7 2 1 2 1 4 Peritonitis 
 
2 
     1 1 1 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 7 1 2 1 1 2 SSI 2 2 
     1 1 2 
 
2 3 2 2 2 2 
  
2 2 
     1 1 1 
 
2 3 2 2 2 2 
  
2 2 
     1 1 1 
 
2 7 2 2 2 2 
  
2 2 
     1 1 1 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 6 2 2 1 1 3 
 
2 2 
     1 1 1 
 
2 4 2 2 2 2 
  
2 2 
     1 1 1 
 
2 3 2 2 2 2 
  
2 2 
     6 2 1 
 
2 6 1 2 2 1 2 Peritonitis 2 2 
     1 2 1 
 
2 4 2 1 2 1 1 
 
2 2 
     2 1 1 
 
2 4 2 2 2 2 
  
2 2 
     2 1 1 
 
2 4 2 2 2 2 
  
2 2 
     2 1 2 
 
2 4 2 2 2 2 
  
2 2 
     
                   
                   2 1 1 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 3 2 2 1 2 
  
2 2 
     1 1 1 
 
2 5 2 2 2 2 
  
2 2 
     1 1 1 
 
2 3 2 2 2 2 
  
2 2 
     1 1 1 
 
2 3 2 2 2 2 
  
2 2 
     
                   1 1 1 
 
2 4 2 2 2 2 
  
2 2 
     1 1 1 
 
2 5 2 2 2 2 
  
2 2 
     5 1 1 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     5 1 1 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 2 
 
2 4 
             
 
1 1 
 
2 4 2 2 2 1 1 
 
2 2 
 
2 
   5 1 1 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
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1 1 
 
2 4 2 2 2 2 
  
2 2 
     2 1 2 
 
2 4 2 2 2 2 
  
2 2 
     1 1 1 
 
2 3 2 2 2 2 
  
2 2 
     5 1 1 
 
2 8 1 2 2 1 2 
 
2 2 
     
 
1 1 
 
2 7 2 1 2 1 4 RTI 2 2 
     
 
1 1 
 
2 3 2 2 2 2 
  
2 2 
     1 1 1 
 
2 3 2 2 2 2 
  
2 2 
     3 1 1 
 
2 4 2 2 2 2 
  
2 2 
     6 1 1 
 
2 8 1 2 1 1 2 
 
2 2 
     1 1 1 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 5 2 2 2 2 
  
2 2 
     1 1 1 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 3 2 2 2 2 
  
2 2 
     1 1 1 
 
2 5 2 2 2 1 4 peritonitis 2 2 
     
 
1 1 
 
2 6 2 2 2 2 
  
2 2 
     5 1 1 
 
2 4 2 2 2 2 
  
2 2 
     1 1 1 
 
2 3 2 2 2 2 
  
2 2 
     1 1 1 
 
2 4 2 2 2 2 
  
2 2 
     1 1 1 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     1 1 1 
 
2 4 2 2 2 2 
  
2 2 
     1 1 1 
 
2 5 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 5 2 2 2 2 
  
2 2 
     1 3 2 
 
2 6 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 5 2 2 2 2 
  
2 2 
     1 1 1 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 3 2 2 2 2 
  
2 2 
     1 1 1 
 
2 3 2 2 2 2 
  
2 2 
     
1 1 1 
 
2 13 2 2 2 2 
 
long HS  
baby sake 2 2 
     1 1 1 
 
2 3 2 2 2 2 
  
2 2 
     1 1 1 
 
2 3 2 2 2 2 
  
2 2 
     
                   1 1 1 
 
2 3 2 2 2 2 
  
2 2 
     7 1 1 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     1 1 1 
 
2 4 2 2 2 2 
  
2 2 
     1 1 1 
 
2 4 2 2 2 2 
  
2 2 
     
                   
 
1 1 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 5 2 2 2 2 
  
2 2 
     5 1 1 
 
2 3 2 2 2 2 
  
2 2 
     1 1 1 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 2 
 
2 3 2 2 2 2 
  
2 2 
     2 1 1 
 
2 4 2 2 2 2 
  
2 2 
     
                   1 1 1 
 
2 3 2 2 2 2 
  
2 2 
     1 1 1 
 
2 4 2 2 2 2 
  
2 2 
     1 1 1 
 
2 3 2 2 2 2 
  
2 2 
     1 1 1 
 
2 3 2 2 2 2 
  
2 2 
     2 1 1 
 
2 3 2 2 2 2 
  
2 2 
     1 1 1 
 
2 4 2 2 2 2 
  
2 2 
     7 1 1 
 
2 4 2 2 2 2 
  
2 2 
     
2 1 1 
 
2 16 2 2 2 2 
 
Long HS – 
Baby sake 2 2 
     1 1 1 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     1 1 1 
 
2 4 2 2 2 2 
  
2 2 
     2 1 1 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 5 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 3 2 2 2 2 
  
2 2 
     1 1 1 
 
2 4 2 2 2 2 
  
2 2 
     5 1 1 
 
2 5 2 2 2 2 
  
2 2 
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1 1 
 
2 4 2 2 2 2 
  
2 2 
     1 1 1 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     5 1 1 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     1 1 1 
 
2 3 2 2 2 2 
  
2 2 
     
                   
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     5 1 2 
 
2 4 2 2 2 2 
  
2 2 
     2 1 1 
 
2 4 2 2 2 2 
  
2 2 
     1 1 2 
 
2 3 2 2 2 2 
  
2 2 
     1 1 1 
 
2 3 2 2 2 2 
  
2 2 
     1 1 1 
 
2 5 2 2 2 2 2 
 
2 2 
     1 1 1 
 
2 3 2 2 2 2 
  
2 2 
     2 1 1 
 
2 6 2 2 2 2 2 
 
2 2 
     
 
1 1 
 
2 3 2 2 2 2 
  
2 2 
     7 1 2 
 
2 5 2 2 2 2 
  
2 2 
     1 1 1 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 3 2 2 2 2 
  
2 2 
     1 1 1 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     7 1 1 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 12 1 2 2 1 2 UTI 2 2 
     
 
1 1 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 2 
 
2 4 2 2 2 2 
  
2 2 
     1 1 1 
 
2 4 2 2 2 2 
  
2 2 
     
                   
 
1 1 
 
2 5 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     2 1 1 
 
2 4 2 2 2 2 
  
2 2 
     
                   
                   
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     
                   
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 6 1 2 2 1 2 
 
2 2 
     1 1 1 
 
2 3 2 2 2 2 
  
2 2 
     
                   
                   
 
1 2 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 2 
 
2 7 2 2 2 2 
  
2 2 
     1 1 1 
 
2 3 2 2 2 2 
  
2 2 
     6 1 1 
 
2 4 2 2 2 2 
  
2 2 
     1 1 1 
 
2 5 2 2 2 2 
  
2 2 
     1 1 1 
 
2 3 2 2 1 1 3 
 
2 2 
     
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     2 1 2 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 3 2 2 2 2 
  
2 2 
     3 1 1 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     1 1 1 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 2 
 
2 4 1 2 2 1 2 
 
2 2 
     
 
1 1 
 
2 6 2 2 1 2 
  
2 2 
     
 
1 1 
 
2 5 2 2 2 1 2 
 
2 2 
     5 1 2 
 
2 5 1 2 2 1 2 
 
2 2 
     
 
1 2 
 
2 4 2 2 2 2 
  
2 2 
     2 1 1 
 
2 5 2 2 2 2 
  
2 2 
     
 
1 2 
 
2 4 2 2 2 2 
  
2 2 
     
 
2 2 
 
2 5 2 2 2 2 
  
2 2 
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1 1 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     
                   
 
1 1 
 
2 3 2 2 1 2 
  
2 2 
     2 1 1 
 
2 5 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 6 2 2 2 2 
  
2 2 
     
                   
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 5 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 2 3 2 4 2 2 2 2 
  
2 2 
     1 1 1 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 3 2 2 2 2 
  
2 2 
     1 1 1 
 
2 5 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 9 2 2 2 2 
  
2 2 
     1 1 1 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     
                   
 
1 1 
 
2 4 2 1 2 1 4 
febrile 
morbidity 2 1 1 2 5 
dengue 
fever 1 
 
1 1 
 
2 5 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 2 
 
2 13 1 2 2 1 2 
septic  
shock 2 2 
     
 
1 2 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 2 
 
2 5 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 3 2 2 2 2 
  
2 2 
     
 
1 1 
 
2 4 2 2 2 2 
  
2 2 
     
 
1 1 
 
1 3 2 2 2 2 
  
2 2 
     
 
 
 
